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lA 
GENERAL INTRODUCTION 
L.M.M. Wolters, R.A. de Man 
Department of Gastroenterology & Hepatology, University Hospital Rotterdam, 
The Netherlands 
Chapter !A 
A chronic hepatitis B infection (HBV) is a potentially progressive liver disease which affects 
around 350 million people world-wide with an annual mortality rate of around 1 million 
people. (1). Together with malaria and tuberculosis it is among the top three of most 
prevalent infectious diseases. The evolution of this viral infection is dependent on the activity 
of the inflammation which is induced by both host and viral factors. HBV may be responsible 
for death due to liver cirrhosis or hepatocellular carcinoma (HCC) with a lifetime risk of 40-
50% in men and 15% in women (2). Universal vaccination which is common practice in over 
80 countries world-wide (3) has the potential to eradicate this viral disease completely and 
prevent HCC. Although vaccination in highly prevalent areas is much cheaper compared to 
the western world, universal vaccination still generates substantial costs per prevented 
infection. Screening for the presence of HBV in pregnant women is a more low-scale 
intervention which is capable of protecting selected neonates by post-natal immunization. 
This program is capable of protecting infants who otherwise run a great risk to become 
chronically infected (4). However, since at present there is a reservoir of millions of people 
who are chronically infected, we are in need of effective antiviral therapies. The main initial 
goal of antiviral therapy should be induction of HBeAg seroconversion and normalization of 
serum transaminases. This results in a low infective individual with a quiescent disease in 
whom the chance of further liver damage has been minimized (5,6). 
Since patients who express active viral replication (as shown by HBeAg positivity and high 
levels of HBV DNA) and/or elevated serum transaminases are at the higbest risk to develop 
complications of the liver disease, therapy should primarily be aimed at this subgroup of 
chronically infected patients. 
More than a decade of intensive research has resulted in tv.ro registered therapies which both 
have limitations. Alpha interferon was the first drug which has proved to cause induction of 
HBeAg seroconversion in 30-40% of patients (7-9). Elevated baseline ALT and lower levels 
of HBV DNA at start of therapy are predictors of a positive response to alpha interferon 
treatment (10). However, the majority of HBV infected patients will not benefit from this 
therapy which is also hampered because of side-effects (11 ). Extensive research in Human 
Immunodeficiency Infected (HIV) patients has resulted in the production of synthetic 
nucleoside analogues that are capable of inhibiting viral replication. Lamivudine, 2'3'-
dideoxy-3'-thiacytidine, is the only registered compound which has proved to be effective in 
both HIV and HBV infected patients. Lamivudine is an obligatory chain terminator that has 
been applied in several large studies causing only few, non-serious, side-effects. It has 
recently been registered for the treatment of chronic liver disease related to HBV (11-14). It 
has proved to be capable of reducing HBV DNA to below levels of detection in insensitive 
assays in the majority of patients after 6 months of therapy (11). The decline of virus is 
accompanied by normalization of serum transaminases and improvement of histology in the 
majority of patients with pronounced viral reduction (12). Even though many patients benefit 
from this therapy, some disadvantages become apparent after several months of lamivudine 
treatment. 
First of all, data on patients who were treated with lamivudine for up to 2 years indicate that a 
part of patients never reaches HBV DNA negativity as measured with insensitive assays 
(11.13.15). Secondly. prolonged larnivudine therapy is hampered by a time-dependent 
emergence ofY1viDD mutations of the polymerase genome of the HBV (16-17). Lastly, even 
though lamivudine induces HBeAg seroconversion in 17% and 27% of patients after 1 and 2 
years of therapy (13). it is durable in only a minority of patients (19). The rebound of viral 
replication which may induce severe liver disease (20) is due to residual virus that is still 
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present in the liver. An important part of this residual virus ( cccDNA) is resistant to 
lamivudine therapy (21,22). Prolongation of therapy could theoretically result in viral 
eradication because of natural tum-over of infected hepatocytes. However, most patients will 
become resistant before complete viral eradication has been accomplished. 
Because alpha interferon and lamivudine can not be applied universally for all chronic 
hepatitis B patients, new approaches should be explored. Most probably, recovery from the 
HBV infection requires a combined action of inhibition of viral replication and turnover of 
infected hepatocytes, either by the immune system or through induction of host defense 
mechanisms by antiviral drugs. To be able to evaluate new therapies however, it is important 
to describe more accurately mechanisms responsible for bypassing the present therapy. 
The objectives of this study were: 
*To evaluate the mechanisms of diminished response to Iamivudine. 
*To evaluate lamivudine therapy and new nucleoside analogue therapies by means of 
mathematical modeling in single drug as well as in combination therapy. 
11 
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Summary 
Hepatitis B virus replicates inside the hepatocyte through an intermediate step of reverse 
transcription mediated by the viral polymerase. We describe 5 nucleoside/nucleotide 
analogues that interfere with the replication mechanisms of the hepatitis B virus. The 
resemblance of nucleoside analogues to natural nucleosides may lead to direct cytotoxicity. 
Therefore, antiviral activity should always be interpreted in the light of cellular toxicity. 
In addition, prolonged therapy with a nucleoside analogue may induce mutations in the viral 
polymerase causing structural and configurational changes of the polymerase resulting in a 
decreased affinity for the nucleoside analogue. Subsequently, the mutated virus is capable of 
renewed replication during continued antiviral pressure of the nucleoside analogue. 
The best antiviral strategy in the future is probably combination therapy, either with several 
nucleoside analogues or with a nucleoside analogue and interferon. 
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Introduction 
Replication of the hepatitis B virus 
Hepatitis B virus (HBV) is a partially double stranded DNA virus converted to covalently 
closed circular DNA ( cccDNA) after uptake into the hepatocyte (Fig I). 
Fig 1 Hepatitis B viral replication inside the hepatocyte. 
export 
reinfection 
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This conversion is most likely catalyzed by cellular DNA polymerases (I, 2). The cellular 
RNA polymerase II regulates transcription of the cccDNA template and forms a greater than 
genome-length mRNA. After translation into the viral polymerase, viral replication continues 
inside the nucleocapside in the cytosol. This polymerase consists of three functional domains 
for priming, reverse transcription and RNAse H activity (Fig 2). There is a fourth domain, 
called the spacer, whose function is not known. 
The polymerase initiates reverse transcription ofmRNA to the(-) DNA strand while adhering 
to the encapsidation signal of the mRNA. The hydroxyl group of tyrosine 96 within the 
priming domain of the polymerase is the acceptor of the first nucleotide of the (-) DNA 
strand. After covalent binding of three nucleotides to tyrosine at the 5' terminus, the 
polymerase complex is dissociated from the mRNA and translocated to a complementary 
sequence in the direct repeat region I (DR!) near the 3' end of the mRNA. The polymerase 
adheres to free nucleotides inside the nucleocapside and incorporates them in the growing (-) 
DNA chain. Meanwhile, RNase H digests the RNA within the RNA-DNA hybrid structure 
leaving a small part of the RNA chain at the 5' terminus (approximately 17-18 nucleotides). 
This RNA oligomer acts as the primer for the formation of the(+) DNA chain. 
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Fig 2 HBV genotype A. The HBV polymerase consists of four domains. The YMDD 
sequence in the C region of the catalytic domain is the main site of interaction with 
nucleoside analogues 
A B 
537 545 ~ 558 578 5<19 595 605 
Pos·ltion 552:YMDD 
The elongation of this chain is again mediated by the viral polymerase and is only partially 
generated. The nucleocapsids can either be retransported into the nucleus or they can leave 
the cell as a complete Dane particle after acquiring the outer envelope membrane. 
The various steps ofHBV replication provide opportunities for antiviral drugs to interact with 
the virus. Nucleoside analogues are chemically synthesized drugs (natural D- or unnatural L-
configuration) (3), which are highly comparable to natural nucleotides. This makes them 
suitable for inhibition of viral replication but, due to possible non-selective inhibition of the 
replication of cellular DNA, also makes them potentially toxic. 
Mechanism of action and efficacy of nucleoside analogues 
Nucleoside and nucleotide analogues can be subdivided into the group of purines (adenosine 
and guanine) and the group of pyrimidines (thymidine and cytosine) which they mimic: 
lamivudine (cytosine analogue), famciclovir, entecavir and ganciclovir (guanosine analogues) 
and the nucleotide adefovir dipivoxil (adenosine analogue). The purine analogues (guanine 
and adenine) are modified cyclic or acyclic sugar configurations whereas the pyrimidine 
analogue lamivudine has an unnatural L-configuration. The group of antiviral compounds 
will hereafter, for the sake of simplicity, be referred to as nucleoside analogues. 
The main action of the nucleoside analogues is interference with the elongation of viral 
chains through competitive inhibition with the viral polymerase. The affinity of the 
nucleoside analogue for the viral polymerase is expressed by the K/Km ratio. Km is the 
constant, which describes binding of the natural nucleoside to the polymerase. Ki expresses 
the affinity of a nucleoside analogue for a polymerase. The nucleoside analogue shows higher 
affinity for the viral polymerase than for the natural nucleoside if the K/Km ratio of the viral 
polymerase is less than l. A K/Km ratio less than 1 indicates that a higher concentration of 
the natural nucleoside with respect to the nucleoside analogue is needed for the two to be 
incorporated in the viral chain equally. After incorporation of the nucleoside analogue, chain 
termination of either the(-) or(+) DNA strand may be accomplished. 
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Fig 3 A Lamivudine; B Famciclovir; C Entecavir; D Ganciclovir; E Adefovir dipivoxil. 
D 
Lamivudine, the negative enantiomer of2'3'-dideoxy-3'thiacytidine (Fig 3A) is metabolized 
to its mono-, di- and triphosphate inside the hepatocyte (4). The rate-limiting step is the 
conversion of the di-phosphate to the active tri-phosphate, the latter comprises only 15% of 
intracellular larnivudine metabolites (4) and can be incorporated in both DNA strands. Since 
the Ki!Krn ratio for lamivudine is> 1, the incorporation of the natural cytosine is favored over 
lamivudine (5). Because of the structure of this analogue, which contains a sulfur atom 
instead of an OH-group at the 3' terminus, the viral chain cannot be elongated and viral 
replication will stop (Fig 4). 
Fig 4 Interference of lamivudine with HBV replication 
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The guanine analogues famciclovir, entecavir and ganciclovir are also metabolized to the 
active triphosphate. However, in contrast to lamivudine, the concentration of the active 
entecavir triphosphate is the highest compared to the mono- and diphosphate metabolites (6). 
In this respect, the drug profile is optimal. Moreover, guanine analogues are capable of 
inhibiting both the priming reaction of the polymerase (7-9), because they bind to the tyrosine 
at the priming site of the polymerase (9), and elongation of both DNA strands of the virus. 
These guanine analogues have a 3 'hydroxyl group used for chain elongation but due to the 
structural changes, which they induce, chain elongation terminates two or three nucleotides 
downstream (10-13). Also, the relatively low intracellular concentration of guanine 
nucleotides may facilitate the incorporation of these nucleoside analogues. 
Famciclovir itself does not have antiviral activity but is deacytylated and oxidized to 
penciclovir (Fig 3B). Intracellularly, penciclovir is phosphorylated into the active tri-
phosphate, with a half-life of 18 hours (13). The D-form of this analogue is more potent than 
the L-form (14, 15) and competes with dGTP for incorporation in the viral chain. The K; is 
approximately three times lower than the Km of the narural nucleoside (14). 
Entecavir is a carbocyclic 2'-deoxyguanosine analogue (Fig 3C). In hepatoma cell lines, the 
active tri-phosphate concentration inside the hepatocyte accounts for 60-80% of all 
nucleotides (6). The tri-phosphate metabolite has a half-life of around 15 hours as measured 
in cell systems (6). 
As shown in in vitro studies of the effect of entecavir and lamivudine on duck hepatitis B 
virus replication, priming is inhibited by entecavir and not by lamivudine (II). Both reverse 
transcription and(+) DNA strand synthesis are inhibited by both compounds, but lamivudine 
exhibits 15-150 and 5-25-fold less activity in inhibiting reverse transcription and (+)DNA 
strand synthesis, respectively, compared to entecavir (II). 
Ganciclovir is an ethoxymethyl guanine with moderate in vitro activity against replicative 
intermediates of the duck hepatitis virus (Fig 3D) (16). One in vitro study on antiviral activity 
of ganciclovir and famciclovir indicates that famciclovir causes more pronounced 
suppression of viral replication than ganciclovir (14). One possible mechanism could be that 
famciclovir is more stable intracellularly than ganciclovir. 
Adefovir dipivoxil (bis-POM-PMEA) is an acyclic nucleoside phosphonate analogue, which 
differs from the nucleoside analogues because this drug contains an incorporated phosphate 
(Fig 3E). After absorption, bis-POM is removed from the parental drug resulting in the actual 
antiviral agent adefovir. For activation of this drug, phosphorylation to the monophosphate, 
can be omitted ( 17) and only one additional step of phosphorylation is required for 
production of the active drug. The intra-cellular half-life of adefovir differs according to the 
cell-system (5-49 hours) (18). In addition, adefovir is believed to stimulate NK-cell activity 
and to induce endogenous interferon production, which may enhance viral eradication (19). 
Covalently Closed Circular DNA (cccDNA) 
The mechanism of conversion of the partially double stranded DNA virus to covalently 
closed circular DNA ( cccDNA) after entry of the virus into the hepatocyte is not completely 
clarified at present. Early reports claim that this process is catalyzed by the viral polymerase 
(20, 21 ). Recent in vitro experiments illustrate that nucleoside analogues probably cannot 
inhibit this conversion to cccDNA ( 1, 2) and that the amount of cccDNA in woodchuck 
hepatocytes does decrease during ddC or lamivudine therapy. but only to the extent of 
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hepatocyte loss in these cell cultures. Another study performed in a recombinant baculovirus-
HepG2 system (22) revealed that the accumulation of cccDNA was markedly inhibited if 
lamivudine was added to the system before infection. This may indicate that lamivudine does 
have some effect on the formation of cccDNA after entry of the virus into the hepatocyte but 
not on accumulation of cccDNA after infection has been established. 
In studies on treatment of ducks infected with the hepatitis B virus with famciclovir and 
ganciclovir, cccDNA was not eradicated during 24 weeks of treatment. It is postulated that 
famciclovir and ganciclovir only affect the internal conversion pathway and not the 
conversion of partially double stranded relaxed virus to cccDNA after entry into the cell (15, 
16, 23). 
Although the results of these studies are not unequivocal, it is plausible to assume that the 
infection of uninfected cells cannot be blocked by nucleoside analogues since this step is 
mediated by cellular polymerases. Only re-entrance of the virus into the nucleus to replenish 
the pool of cccDNA may be inhibited by nucleoside analogues as a result of interference with 
reverse transcription. In clinical situations, this implies that, if therapy is administered long 
enough, the pool of cccDNA may eventually vanish. Studies of woodchucks indirectly 
showed that entecavir might have a direct effect on the cccDNA pool; induction therapy 
followed by maintenance therapy (one dose once a week) for 52 weeks caused undetectable 
markers of the hepatitis B virus in all treated animals. After withdrawal of the drug, five out 
of six woodchucks showed absence of the hepatitis B virus untill7 weeks after withdrawal of 
therapy (25). This may indirectly indicate that the cccDNA pool has been reduced drastically. 
The exact mechanism of entecavir on cccDNA still needs to be determined. 
New studies on woodchucks treated with adefovir have also indicated that the cccDNA pool 
is very stable and cannot be decreased by interference of this adenine nucleoside analogue 
during 24 days of therapy. During longer therapy, adefovir may have more effect on cccDNA 
since this drug is also capable of inducing NK-cell activity and stimulating endogenous 
interferon production. These features may help to kill infected hepatocytes and diminish the 
pool of cccDNA (26). 
Safety 
The safety of nucleoside analogues should be evaluated in the light of in vitro data on 
cytotoxicity and the affinity of these analogues for cellular polymerases. The therapeutic 
index is an in vitro ratio, which expresses the concentration of the drug which kills 50% of 
the hepatocytes in relation to the concentration of the drug needed to inhibit 50% of the viral 
replication (CCsoiiCso). If the K/Km ratio is known for cellular polymerases, it provides 
information about the affinity of the analogue for cellular polymerases, possibly causing 
toxicity. Several cellular polymerases are involved in the replication of the cellular genome. 
Polymerase y is responsible for replication of mitochondrial DNA. Polymerase a and 0 are 
mediators of genome replication whereas polymerase j3 is involved in repair of the genome. 
Polymerase e is most likely involved in both replication and repair. Insight into interference 
of the nucleoside analogues with these different cellular enzymes is essential for 
understanding and evaluating the potential toxicity. 
As observed during therapy with fialuridine, a thymidine analogue, the close resemblance to 
natural nucleotides may cause serious clinical problems (27, 28). The therapeutic index of 
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fialuridine is satisfactory, as shown in in vitro studies (29). However, fialuridine exhibited an 
high affinity for polymerase y, which incorporates the drug into mitochondrial DNA (30). 
This results in a completed but deviant DNA chain. Due to this aberrant DNA, oxidative 
phosphorylation can no longer take place, causing lactic acidosis, neuropathy, myopathy, 
pancreatitis and even death. Either one of the polymerases can incorporate fialuridine with a 
higher affinity than the natural nucleoside ( dTTP) (30). Because polymerase y has the lowest 
Ki of these polymerases, incorporation into this polymerase seems to cause the biggest 
problem. Even though polymerase y, o and 8 exhibit exonuclease activity (31), incorporated 
:fialuridine does not seem to alter the tri-dimensional structure in such a way that the 
disruption is recognized and removed by the exonuclease activity. Drugs like lamivudine, 
entecavir, famciclovir, ganciclovir and adefovir do not exhibit, or only to a lesser extent, 
these qualities (32-34). 
Resistance 
Five subsequent domains encompassing nucleotides 423 through 605 (genotype A) (A, B, C, 
D and E) are highly conserved in both the RNA-dependent HBV DNA polymerase and RNA 
polymerases (Fig 2). For the Human Immunodeficiency Virus (HIV), which contains a 
polymerase that is highly comparable to the hepatitis B polymerase, it is proposed that 
domains A, C and D are directly involved in nucleoside binding; domains B and E may be 
involved in positioning of the primer and the template (35). Structural changes in these 
domains in particular may be responsible for resistance to nucleoside analogues. 
Table 1 Nucleotide changes inducing resistance to lamivudine and famciclovir in 
genotype A HBV. 
Lamivudine Polymerase domain Famciclovir Polymerase domain 
I401S 
F514L 
V521L 
L528M 
V528M 
T532S 
A548V 
M552I 
M552V 
M552S 
V555I 
S561T 
L577V 
B-domain 
B-domain 
B-domain 
B-domain 
C-domain 
C-domain 
C-domain 
C-domain 
C-domain 
22 
V521L 
P525L 
L528M 
L528V 
T532S 
B-domain 
B-domain 
B-domain 
B-domain 
B-domain 
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Lamivudine and famciclovir have been extensively evaluated for the emergence of mutations 
in the polymerase gene in vitro and in vivo (Table I). Prolonged lamivudine therapy is 
hampered by the emergence of mutations at the catalytic site of the polymerase gene, the so 
called YMDD motif in domain C. In this motif, the methionine at position 552 is replaced by 
valine or isoleucine; the former being most often associated with a mutation in the B-domain 
of the polymerase gene (substitution of a leucine for a methionine nucleoside at position 528) 
(36-45). This mutation causes a change in the tri-dimensional structure of the polymerase; 
subsequently lamivudine is less efficiently incorporated into the viral chain, because of 
reduced spatial fit in the polymerase structure. As a result, reverse transcription proceeds with 
natural nucleosides and a rebound of viral replication occurs. Other mutations in both the B-
domain and the C-domain of the polymerase gene caused by lamivudine have been described 
(Table!). 
Famciclovir induces mutations in the B-domain. The mutation at position 528 (leucine 
replaced by either methionine or valine) is also known to occur during lamivudine therapy 
and may therefore cause cross-resistance (43-46). 
A search for new antiviral therapies should focus on the different mechanisms of action of 
antiviral drugs to bypass the problem of resistance. Entecavir and adefovir have proven to 
have a continuing effect on lamivudine resistant strains in vitro (41, 47) and in vivo (48) 
(Table 2). Even with the structural change induced by lamivudine, the viral polymerase is still 
capable of incorporating other analogues into the catalytic site. Until now, follow-up data on 
treatment with entecavir, ganciclovir and adefovir have not shown resistance in vivo; 
however, these agents have only been administered for a short period. If entecavir and 
adefovir exhibit stronger viral suppression than lamivudine, as has been observed in in vitro 
studies (11, 49), combined with a different interaction of the analogue with the polymerase, it 
is reasonable to assume that the emergence of mutations may take longer to evolve. 
The rate at which mutations emerge is influenced by several factors and may be lower if 
stronger viral suppression is achieved (50). Secondly, the reverse transcriptase does not have 
a proof-reading capacity to excise nucleoside analogue monophosphates which have been 
incorporated (51, 52). This makes the virus more prone to mutations. 
Table 2 Fold increase in Ki of nucleoside analogues for lamivudine induced mutants 
compared to wildtype. 
Nucleoside analogue wildtype M552I M552V L528M L528MIM552V 
Lamivudine 44 I 8.0 19.6 2.6 25.2 
Famciclovi?9 1.1 3.1 3.1 2.5 
Adefovir44 1.3 2.2 2.3 0.79 
Clinical application 
Data on results from in vitro studies and animal models lead the way to optimal application of 
new nucleoside analogues in chronic hepatitis B patients. Lamivudine has proven its worth by 
inducing strong inhibition of viral replication, reduction of liver inflammation and 
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improvement of liver histology (53-56). Recently it has been registered for the treatment of 
chronic hepatitis B. However, the emergence of mutations during long-term rnonotherapy 
prevents the drug from being used as a single agent to eradicate the virus from the liver (36-
44). 
Although promising in in vitro studies, famciclovir and ganciclovir, which have established 
their value as therapies for herpes viruses and the cytomegalovirus, respectively, have only 
limited in vivo effect against the hepatitis B virus (57-59). Monotherapy with these agents has 
therefore been abandoned. Possibly, they can still be used as a part of nucleoside analogue 
combination therapy (60). In contrast, adefovir dipivoxil and entecavir, which both have a 
good safety profile in vitro, have proven their in vivo efficacy in chronic hepatitis B patients 
also (61-63). They are being evaluated in phase III studies at the moment. In early studies, the 
use of adefovir dipivoxil in the dose range 60 to 120 rng once daily was limited by 
nefrotoxicity. Present studies are ongoing with dosages between 10 and 30 mg to avoid this 
side-effect (64). 
Conclusions 
Optimal antiviral therapy for the maJonty of chronically infected hepatitis B patients, 
resulting in loss of HBV DNA, HBeAg, and eventually HBsAg, cannot be obtained with 
nucleoside monotherapy. New nucleoside analogues enter the area of clinical application on a 
regular basis and a balance should be found between safety and optimal viral suppression. 
Combinations of nucleoside analogues with slightly different mechanisms of interference 
with the viral polymerase may prevent or at least delay the moment of the development of a 
mutant virus. This would make it possible to clear cccDNA from hepatocytes by natural 
mechanisms, such as hepatocyte division and possibly intrinsic immunity, to completely 
eliminate the virus. 
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Chapkr 2 
Summary 
Rationale and aim Recently, we described a first order decay model for the description of a 
decrease in viral load during treatment with lamivudine for a chronic hepatitis B virus infection 
(HBV). However, more frequent sampling of viral load during the first month of treatment 
shows a hi-phasic viral decline. We therefore compared several mathematical models which are 
currently in use to describe the dynamics of various viruses and treatments. 
Methods HBV DNA positive chronic hepatitis B patients were treated with larnivudine 150-600 
mg daily for four weeks. During the first two days, blood samples were drawn every six hours, 
then daily during the first week and weekly during the following three weeks. HBV DNA was 
measured with the Digene Hybrid Capture II HBV DNA test and the sensitive Roche PCR 
assay, both calibrated on the Eurohep standard, 
Results Our HBV DNA data are most accurately described if we use the hi-phasic model 
previously described by Neumann et al. while introducing all consecutive data of all patients 
simultaneously (mixed effects model). This results in an effectiveness of blocking of viral 
replication of93%, a half-life of free virus of 17 hours and a half-life of infected hepatocytes of 
7 days in patients treated with 150 mg oflamivudine. 
Conclusion HBV dynamics during treatment with lamivudine can be explained by blocking of 
virion production with or without blocking of de-novo infection. The hi-phasic model as 
described by Neumann et al. in combination with frequent blood sampling, provides the most 
accurate fit and can be used -to compare new nucleoside analogue profiles to lamivudine 
therapy, 
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Introduction 
Io patients who are chronically infected with the hepatitis B virus, response to therapy can be 
described in various ways. Most larger studies report on log viral decline during a specified 
time-interval (1-5). However, since the early studies were based on viral decline with 
insensitive assays, response to therapy most often resulted in description of the percentage of 
patients who became negative with this assay. The introduction of sensitive Polymerase Chain 
Reaction (PCR-) assays, has provided us with a tool to evaluate viral decline in more detail (6). 
By using these assays, it has been shown that patients who were considered responders in the 
early studies, still may have a considerable amount of virus in serum even after several months 
of therapy (7). 
Mathematical description of viral decline during therapy is a second option to compare the 
response to therapy between individual patients and groups of patients. Models that describe 
the biological sequence of events which take place during antiviral therapy for chronic hepatitis 
B patients have been developed since 1995 (8, 9). In one of these models (8) we described a 
frrst order decay model of viral decline during lamivudine therapy; however, frequent sampling 
during the first month of therapy has revealed a bi-phasic viral decline. The most recent model 
is a model which was originally developed for the description of viral decline in chronic 
hepatitis C patients during alpha interferon therapy (10). Viral decline in chronic hepatitis B 
patients who are treated with adefovir dipivoxil has proven to fit well with this model (11). 
In our study, we evaluated the three different published models on description of viral decline 
during treatment in chronic hepatitis B patients. Moreover, we compared two different 
statistical techniques to compare the results of the fit of the model which fitted the observed 
data most accurately. For comparison of mathematical models and statistical techniques, we 
used data of chronic hepatitis B patients who were treated with lamivudine. 
Patients and methods 
Patients 
Twenty-one chronic hepatitis B patients with active viral replication (HBV DNA > 1.5x!06 
genome equivalents/ml (geq/ml)) were randomly assigned to receive either 150 mg (n~ll) or 
600 mg (n~ I 0) of lamivudine daily for 4 weeks. After this initial treatment period all patients 
continued to receive 150 mg lamivudine daily. Randomisation was computer-generated and 
randomisation labels were kept in sealed non-opaque randomisation envelopes. Blood samples 
were drawn at screening, baseline and at F6, 12, 18, 24, 30, 36,42 and 48 hours. Subsequently, 
blood samples were obtained daily during the first week and at day 7, 10, 14, 21 and 28. 
Samples were snap frozen and stored. At each visit HBV DNA was assessed. 
HBV DNA measuremenl 
HBV DNA was quantified with a Digene Hybrid Capture tube liquid hybridisation assay 
(calibrated on the EUROHEP standard (12)). If HBV DNA became undetectable with this 
assay (limit of detection 1.5xi06 geq/ml) during lamivudine treatment, it was reassessed with 
the quantitative PCR (Roche, Amplicor Diagnostics, Almere, The Netherlands calibrated on the 
EUROHEP standard; a lower limit of detection of I 000 geq/ml). 
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Models for viral dynamics 
The viral dynamics for the t\Vo dosage groups were analysed by means of a single exponential 
model (Zeuzem et al (8)) and a bi-phasic model with a flat second phase (hereafter referred to 
as bi-phasic model 1) by Nowak et al. (9). Both models (8,9) described the viral decline in 
chronic hepatitis B patients treated with lamivudine. We compared these t\Vo models with a hi-
phasic model defined by Neumann et al. (I 0) for hepatitis C (hereafter referred to as bi-phasic 
model 2) which was also used, with some modifications, for the treatment of chronic hepatitis 
B patients with adefovir by Tsiang et al. (II). 
Both the exponential and the bi-phasic model I and 2 are based on three differential equations 
which describe the equilibrium between uninfected hepatocytes (T), infected hepatocytes (I) 
and free virus M (6). 
dT/dt= s-dT-(l-ll)J3VT 
dVdt= (l-ll)J3VT-ol 
dV/dt= (1-e)pl-cV 
s = production rate of uninfected cells 
d = death rate of uninfected cells 
J3 
0 
= infection rate of uninfected cells by the free virus 
=death rate of productively infected cells 
p 
c 
=viral production rate from infected cells 
= clearance rate of the free virus 
£ =effectiveness oflamivudine in blocking virion production from infected cells 
11 =effectiveness oflamivudine in blocking de novo infection ofuninfected cells 
A pure exponential decay model (8) is based on total inhibition of viral production by the 
antiviral agent (e=l) and possibly total inhibition of infection of uninfected cells (11=1), 
resulting in the following decay function: 
V(t)= Voe"' 
For the bi-phasic model I (9) it was assumed that the number of infected cells (!) does not 
considerably decrease during early treatment and reaches a plateau level (1-e)Vo during the 
treatment of hepatitis B patients with lamivudine. 
V(t)= (1-e)Vo +eVo e~' 
For the bi-phasic model2 (I 0) it is assumed that: 
1. the number of uninfected cells (T) does not considerably increase throughout the first 4 
weeks of treatment. 
2. the major antiviral effect of lamivudine is to partially block virion production from infected 
cells (O<e<l) thus causing a rapid decline in the first few days with the slope depending on 
clearance of free virus (c). 
This results in the following equation: 
V(t)= Vo{Aexp[-A.,t]+(l-A)exp[-Aot]} 
A = (ec-A.2)/( A.,-A.,) 
A.,~ = Yo{(c+o)±[(c-8)2+4(1-e)(l-ll)co]"} 
Neumann et al. (10) assumed that 11=0 (no block of de novo infection of uninfected cells), 
while Tsiang eta!. (ll) assumed that lj=l (complete block of infection ofuninfected cells). We 
considered both assumptions as a possibility and we report a minimal and maximal estimate for 
8 which is the only variable significantly dependent on ll· 
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Statistics 
The three models were fitted with mixed modeling techniques using random effects. This 
allows for analysis of the entire data set with the possibility to estimate dose specific 
dynamics parameters and curves. The random effects (subject specific corrector factors) 
included for each parameter give the individual deviation for the dose-specific curves. 
Previous analysis of dynamic models used the method of an individual fit per patient in 
contrast to our method analysing group effects using the entire data set. In order to compare 
these analysis methods, we applied individual and group fits using the hi-phasic model 2. 
Mixed modeling implies a group wise analysis while introducing random effects on all 
parameters and is most precise from a statistical point of view since all variables as well as all 
patient data are related and influenced by each other. Based on these data, group effects can 
be derived and compared. 
For the exponential decay, PROC MIXED in SAS 6.12 was applied. Non-linear modeling 
was used to fit the bi-phasic model 1 and the bi-phasic model 2, executed in the NLINMIX 
macro in SAS 6.12. 
To quantitatively describe the accuracy of the several models. Akaikes Information Criteria 
(AIC) were assessed (13). The AIC represents the relation between the 2log likelihood and 
the number of degrees of freedom. The AIC closest to zero indicates the smallest residuals 
from the observed HBV DNA data, resulting in the best fit. 
Results 
All the patients showed a very similar bi-phasic viral decline pattern, except for patient 3, who 
had a rebound in viral replication after an initial decline (Fig 1). 
All treated patients were analysed and corrections of dose were accounted for. To compare 
different modeling techniques, the following results and the results in both tables describe 
patients treated with 150 mg oflamivudine. 
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Fig I Viral decline of individual patients. All patients. except patient 3 (in dashed line). show 
a consistent pattern of decline. To compare the three different models, patient 3 is 
included in the analysis (Table 1 ). However, to compare the individual fitting with the 
mixed effects approach of the hi-phasic model 2, this patient is excluded (Table 2). 
Since this patient shows a rebound in viral load, the death rate of infected cells (0) 
which partially determines the viral decline during the second phase carmot be 
calculated using individual fitting techniques. 
lOEIIr----------------, 
dnys nftorstlrt ofthor.lpy 
Comparison of the fit of the different models 
Both the visual assessment (Fig 2) as well as the AIC of the exponential model (-456) and the 
hi-phasic model I ( -359) show that these are not accurate fits of our patient data. In contrast, 
the AIC of the bi-phasic model 2 ( -220) as well as the observed fit to the data-points shows 
that this model does represent the best fit for these patient data compared to the other models 
(Fig 2 and Table 1 !). 
The exponential model yields in a viral halflife of 108 hours (Table I). For the bi-phasic model 
1, the death rate of free virus and the derived viral half life is 29 hours. This viral half life 
reflects the initial first phase of rapid viral decline since the second phase is expressed by a 
constant (p) which does not add to further viral decline. In the bi-phasic model2, effectiveness 
in blocking viral production (e), half-life of free virus, and halflife of infected cells are 0.915 
(91.5%), 15 hours and 186 hours respectively (Table 1). 
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Table I Fitting of HBV decline during lamivudine treatment with the 3 models based 
on the group mixed effect approach (including patient 3). 
Exponential decay: 
Voe -ct 
TY, (In2/c) 
Nowak: 
(1-e)Vo+£ Voe"" 
£ 
TY, (In2/c) 
Neumann: 
Yo (Ae"'l '+(1-A)e-":2') 
£ 
TY, (In2/c) 
TY, (In2/8) (ift]=O) 
V0 =initial viral load 
c = clearance rate of free virus 
!50 mg/day 
mean fit ( s.e.) 
108 hrs {CI 89-139) 
0.973 (0.008) 
29 hrs {Cl 25-35) 
0.915 (0.016) 
15 hrs {CI 12-19) 
186 hrs (= 8 days) {Cl 140-277} 
0 = death rate of productively infected cells 
c = effectiveness oflamivudine in blocking virion production 
CI = 95% Confidence Interval 
s.e. = standard error 
AIC = Akaikes Information Criteria 
T~ = half-life 
overall fit 
(AI C) 
-456 
-359 
-220 
Fig2 HBV DNA of individual 9 fitted by the exponential model (diamonds), the bi-phasic 
model I (circles) and the hi-phasic model2 (crosses). The bi-phasic model2 provides 
the best fit of the observed data (squares). 
'OE''~o -,~-, -, -,-. -,,,-, -,,,-, -,,-_, -,1.,-6 -,.,.-,,,,....,,,.-..,,_,~20,--J20 
Days af1or t.lort of tho ropy 
Comparison of individual and group-wise fitting 
If patients are fitted individually, a variable delay in viral decline can be introduced. 
Mathematically a variable delay could also be applied for the mixed effects approach, but this 
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results in too many variables in relation to the amount of patient data. For the mixed effects 
approach, we therefore introduced a fixed delay in viral decline (six hours): the first HBY DNA 
measurement after start of therapy was at six hours. Patient 3 is the only patient who does not 
show a bi~phasic viral decline; the initial fast decrease of viral replication is followed by a 
rebound in viral load. Therefore, the death rate of infected hepatocytes (8) which partially 
determines the viral decline during the second phase can not be calculated for this individual 
patient. To compare the individual and group-wise fitting, patient 3 is excluded. 
Individual modeling for the bi-phasic model 2 which is dependent on c, 0, E and 11· results in an 
effectiveness in blocking viral production of 0.922 (92.2%), half-life of free virus of 16 hours 
and a half-life of infected cells of 178 hours. If a group-wise fit of the hi-phasic model 2 is 
applied, the effectiveness in blocking viral production (e), half-life of free virus, and halflife of 
infected cells are 0.928 (92.8%), 17 hours and 177 hours respectively (Table 2). If patient 3 is 
included into the mixed effects analysis, half-life during the second phase is slightly elongated 
(186 hours versus 177 hours; Table I and 2). 
Table 2 Parameter estimates based on the hi-phasic model 2 with individual non-linear 
fitting and mixed effect group fitting (excluding patient 3). 
Bi-phasic model2 (individual fit): 
Yo (Ae-'1'+(1-A)e":z') 
In (Vo) 
c (with a variable delay) 
8 (ifT]~O) 
8 (ifT]~l) 
e (with a variable delay) 
TY, (ln2/c) 
TY, (ln2/8) (ifT]~O) 
Bi-phasic model2 (group fit): 
Yo (Ae'I '+(1-A)e":z') 
In (Vo) 
c (with fixed delay of6 hours) 
8 (ifT]~O) 
8(ifwlJ 
e (with fixed delay of6 hours) 
TYo (ln2/c) 
TY, (ln2/8) (ifT]~O) 
V0 initial viral load 
c = clearance rate of free virus 
0 =death rate of productively infected cells 
11 =effectiveness oflamivudine in blocking 
de novo infection ofuninfected cells 
150mg/day 
mean fit 
20.22 (s.d. 2.23) 
1.238 (s.d. 0.590) 
0.099 (s.d. 0.062) 
0.092 (s.d. 0.049) 
0.922 (s.d. 0.032) 
#16 hrs(range 9-42) 
#178 hrs (~7 days)(range 84-768) 
20.13 (s.e. 0.65) 
0.979 (s.e. 0.11) 
0.094 (s.e. 0.014) 
0.086 (s.e. 0.014) 
0.928 (s.e. 0.015) 
17 hrs (CI 14-22) 
177 hrs (~7 days)(CI 137-250) 
CJ 95% Confidence Interval 
s.c. = standard error 
s.d. = standard deviation 
# =median 
z =effectiveness oflamivudinc in blocking virion production 
T~ = half-life 
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Discussion 
Modeling gives us a tool for evaluation of the effect of an antiviral therapy, by means of 
parameters of effectiveness and both viral half-life and half-life of infected cells. This is in 
contrast with rough data on viral decline during therapy which are merely a surrogate marker of 
the effectiveness of the drug. In addition, modeling probably can be used to predict response to 
therapy in individual patients and to compare different nucleoside analogues or nucleoside 
analogue combinations. 
The aim of this study was to examine which model describes the HBV DNA data most 
accurately and to explore the best available statistical technique (mixed modeling techniques 
using random effects versus individual fits) to describe the decline of the hepatitis B virus 
during lamivudine therapy. The mixed modeling technique shows that the hi-phasic model 2 
most accurately reflects the observed data (AIC closest to zero and observed by visual 
assessment) compared to the exponential model and the hi-phasic model 1. 
Our data are in agreement with viral decline during adefovir therapy as described by Tsiang et 
al. (11). The model which has been used in this publication is comparable to our hi-phasic 
model 2. However, frequent blood withdrawal seems to be essential to accurately describe the 
biological phenomena. Effectiveness (c) of adefovir in this study was 0.993. The effectiveness 
of lamivudine as calculated by mixed modeling in our study is lower: 0.928. In contrast, the 
mean viral half-life during the first phase in the adefovir study is 1.1 day and the half-life of 
infected cells during the second phase is 18.2 days. This is considerably longer than 17 hours 
for the first phase and 177 hours for the second phase in our study. We calculated a duration of 
the initial phase of2.7 days, such that the change from the first to the second phase occurs early 
in the first week as can be observed from our data. Tsiang et al. conducted the first HBV DNA 
measurement after one week of therapy, which may explain these discrepant findings. Although 
the exact frequency of observations that is required for optimal modeling needs to be 
determined yet, the first days of therapy are important and need to be documented adequately. 
From our data. we would recommend minimal blood withdrawal at day 0, day 2, 4 and 7. 
The exponential model provides the least precise fit of the three applied models. In vitro assays 
show that nucleoside analogues, lamivudine in particular, probably cannot prevent infection of 
uninfected cells (14,15). The conversion of the double stranded viral genome to cccDNA is 
mediated by a cellular polymerase for which lamivudine has much less affinity than the natural 
cytosine (16,17). Also, complete inhibition of viral replication would very soon lead to 
disappearance of the virus from the blood and eventually from the liver. In contrast, long-term 
follow-up of patients during lamivudine therapy shows that a considerable proportion of these 
patients retain a moderate viral activity, with detectable HBV DNA by insensitive assays after 
several months of treatment (6). 
The hi-phasic model 1 takes into consideration the change in half-life of the virus during 
treatment. However, the fit of our patient data shows that the initial fast viral decline is not 
followed by a complete steady state of virus production and degradation, which is expressed in 
this model. Although viral decline is slower during the second phase, a continuing decrease of 
viral load in serum can still be observed. 
The assumptions made in the hi-phasic model 2 also hold true for our patient group. The major 
effect of lamivudine is near complete blocking of replication of the virus in hepatocytes, 
causing a reduction of release of free virus into the peripheral blood. However, lamivudine does 
not influence the degradation of free virus since this drug has no immunomodulating activity 
nor does lamivudine have a toxic effect on infected hepatocytes. We can not rule out a possible 
37 
Chapter 2 
effect of lamivudine on blocking infection (11 varying between 0% and 100%), but clearly the 
viral kinetic data can be fit without assuming such an effect. 
According to our data, application of the mixed modeling technique for the bi-phasic model 2 
provides an optimal fit for description of viral decline in chronic hepatitis B patients during 
lamivudine therapy, Lamivudine blocks production of virus (e), which we can measure, In 
addition, lamivudine may also have some direct effect on the infection of uninfected cells. 
However, this cannot be shown with the bi-phasic model 2, since the second phase of viral 
decline, during which lamivudine could interfere with infection of uninfected cells, is 
dependent on too many variables. 
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Chapter 3 
Summary 
VIral decline during lamivudine therapy in chronic hepatitis B patients is bi-phasic. We studied 
the influence of lamivudine dose and baseline characteristics on parameters obtained from a 
mathematical model. 
Methods Chronic hepatitis B patients were randomised to receive 150 mg (group 1; n=ll) or 
600 mg (group 2; n= 1 0) lamivudine daily for four weeks. HBV DNA was measured frequently 
with the Digene Hybrid Capture II test and the Roche PCR assay. 
Results Description of viral decline in our closely monitored patients by means of the mixed 
effects approach with both the bi-phasic model and a piecewise linear regression model resulted 
in a good fit. Baseline AL T was significantly related to the slope of the second phase of viral 
decline. Previous lamivudine treated patients showed a significant slower :first phase than 
patients naive to lamivudine treatment. 
Conclusion The initial observed difference in viral decline between 150 mg and 600 mg of 
lamivudine disappeared when baseline AL T was taken into account. This strengthens the 
hypothesis that the level of intrinsic activity is related to the turnover of infected hepatocytes. 
Moreover, reintroduction of lamivudine in previously lamivudine treated patients should be 
considered carefully. 
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Introduction 
Larnivudine is capable of inhibiting hepatitis B viral replication in the majority of patients if 
doses over 100 mg daily are applied (1, 2). Previous studies on the effect oflamivudine were 
based on description of the percentage of patients with a viral decline below the limit of the 
insensitive assay used (1- 4). However, recent studies, which were based on mathematical 
description of viral decline, are able to reveal more detailed differences between patients (5-7). 
A bi-phasic model which was originally evaluated for hepatitis C viral decline during alpha 
interferon therapy (7) has proven to describe adequately viral decline in chronic hepatitis B 
patients treated with nucleoside analogues also (8,9). In contrast to the previous described data 
in adefovir therapy (8), we tried to increase the accuracy of the estimates by increasing the 
frequency of first week sampling for HBV DNA levels. 
In analogy to the response of chronic hepatitis B patients to alpha interferon therapy, which is 
largely dependent on baseline factors (l 0-12), lamivudine treated patients also show a higher 
chance ofHBeAg seroconversion if intrinsic activity against the HBV, as reflected by elevated 
serum transarninases, is present at baseline (11,13). Repeated alpha interferon therapy in 
previous non-responders induces a similar percentage of HBeAg seroconversion compared to 
treatment of alpha intetferon naYve patients (14). However, previous failure to lamivudine 
therapy could alter the response of repeated therapy due to altered characteristics of the virus or 
selection of patients. In order to evaluate the effect of baseline factors on response to therapy, 
we evaluated high and low dose lamivudine treated patients. 
Patients and methods 
Patients 
Eligible patients included men and women between 18 and 70 years of age who had a biopsy-
proven chronic hepatitis B virus infection and who were positive for HBsAg. HBV DNA had to 
be >l.5xl06 genome equivalents/ml (geq/ml). Patients were excluded if they had detectable 
antibodies against the hepatitis C or D virus or if they were co-infected with the Human 
Immunodeficiency Virus (HIV). Patients with decompensated liver disease, liver diseases with 
other aetiologies or other serious concomitant medical illnesses were excluded as well. The 
Medical Ethics Committee of the University Hospital Rotterdam approved the study. All 
patients had to give vvritten informed consent. 
Twenty-one patients were randomly assigned to receive either 150 mg or 600 mg oflamivudine 
daily for 4 weeks. After this initial treatment period all patients continued to receive 150 mg 
lamivudine daily. Randomisation was computer-generated and randomisation labels were kept 
in sealed non-opaque randomisation envelopes. All patients were screened one week before 
start of treatment for eligibility. Patients were admitted to the hospital for the first two days 
(day 0-2). Blood samples for HBV DNA measurement were drawn at screening, baseline and at 
t=6, 12, 18, 24, 30, 36,42 and 48 hours, daily during the first week and at day 7, 10, 14,21 and 
28. 
Virology 
HBV DNA was quantified with a Digene Hybrid Capture tube liquid hybridisation assay 
(calibrated on the EUROHEP standard (15)). If HBV DNA became undetectable with this 
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assay (limit of detection 1.5xl06 geq/ml) during lamivudine treatment, it was reassessed with 
the quantitative PCR (Roche, Amplicor Diagnostics, Almere, The Netherlands calibrated on the 
EUROHEP standard with a lower limit of detection of I 000 geq!ml). HBV polymerase mutant 
analysis was performed with the INNO-LiPA DR-strip (Innogenetics, Gent, Belgium) (16). 
Description of viral decline 
The viral dynamics is described by an exponential bi-phasic model as previously described by 
Neumann et al. (7). In short, viral decline in the hi-phasic model is described by the following 
equation: 
V(t)= Vo{Aexp[ -A.,t]+(l-A)exp[-A.,t]} 
where 
A., =slope of the first phase of viral decline 
A., = slope of the second phase of viral decline 
A = (ec-A.,)/( A. 1-A.2) 
A., 2 = Yo{(c+o)±[(c-8)2+4(1-e)(l-'l)cot} 
V o = initial viral load 
T =time 
i5 =death rate of productively infected cells 
c = clearance rate of the free virus 
e =effectiveness oflamivudine in blocking virion production from infected cells 
11 =effectiveness oflamivudine in blocking de novo infection of susceptible cells 
The second slope is dependent on 0 only if lamivudine is assumed to be capable to completely 
block the novo infection of uninfected hepatocytes (i.e. if 11 = 1, than A.2 = o). However. if 
lamivudine does only in part or not block infection of uninfected hepatocytes at all, the second 
slope is expressed as A2 and dependent on c, 8, £and fl. 
A piecewise linear model was also fitted based on the following equation: 
log(V(t) )= a+b*t+c,*(t-tb)*(t>tb) 
log (V(t))= a +b*t 
log (V(t))= (a-c,*tb) +(b+c2)*t 
where 
Yo =initial viral load 
a =log V (t=O) 
ift:Stb 
ift>tb 
b = slope of the first phase of viral decline 
b+c2 =slope of the second phase of viral decline 
t =time 
tb = break point 
Statistics 
The entire data set was analysed with mixed modeling techniques using random effects to 
estimate dose specific dynamic parameters and curves. The random effects (subject specific 
corrector factors) included for each parameter, give the individual deviation for the dose-
specific curves. The data consist of 16 measurements per subject (n=21) (16x21=336 
measurements). The mixed-effects model uses 4 fixed parameters (or 2x4 fixed parameters 
when extending the model with dose, see below) and 10+ 1 random parameters, that is -5% of 
the data. 
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In contrast, the separate fit of the bi-exponential or the piecewise linear model to each of the 
21 subjects uses 2lx4 = 84 parameters. Moreover a separate fit does not take into account the 
obvious similarities among the individual curves. This is useful when one is interested in 
modeling the behavior of a particular, fixed set of individuals, but it is not adequate when the 
observed individuals are to be treated as a sample from a population of similar individuals, 
which constitutes the majority of applications involving grouped data. In our case, the interest 
is in estimating the average behavior of an individual in the population and the variability 
among and within individuals, which is precisely what mixed-effects models are designed to 
do (17). 
For both models, non-linear mixed modeling was used, applying the NLINMIX macro in 
SAS 6.12. Akaikes Information Criteria (AI C) (18) were used to describe the accuracy of the 
models in relation to the observed patient data. To investigate a possible effect of baseline 
factors (pre-treatment ALT-values Qx ULN (Upper Limit of Normal) versus >2xULN, 
previous lamivudinc treatment, Body Mass Index (BMI) and race) on the viral decline, 
covariates were included to the piecewise linear model. Each fixed parameter, for example A-2 
in the exponential bi-phasic model, is written as a sum of two parameters: one to explain the 
level of this parameter, A2.1cvc1, and one to explain the difference between the dose=150 and 
dose =600, A.2,6oo, i.e. 
r A.::!,lcvcl 
A.,= ~ 
, if dose=l50 
l A2.1~" + Az.60o , if dose=600 
Likewise, the model is extended with baseline factors simply adding an extra parameter to 
explain the difference, for example between high ALT and low ALT: 
r A.'·'"'' , if dose= 150 and AL T low 
I A2,1evel + A.2ALThigh , if dose= 150 and AL Thigh 
A.,= ~ 
I A.2.1cvel + A.2,600 
l A2,levcl + A.2.600 + A.::!AL Thigh 
, if dose=600 and AL T low 
, if dose=600 and AL Thigh 
Theoretically, the baseline variables could be incorporated into the exponential hi-phasic 
model, but with these extra variables, convergence could not be reached because of the 
complexity of the random-effect model and the number of variables. Instead, point estimates of 
the exponential hi-phasic model, derived from the non-linear fit per patient using ProcNLIN 
in SAS, were compared between groups with the non-parametric Mann Whitney test. 
Significant difference was achieved if p<0.05. 
Patient 3 was the only patient with a rebound in viral replication during the second phase. For 
this individual patient, the exponential hi-phasic parameter of the second phase can not be 
interpreted. On the other hand, the course of viral decline represents one of the possible 
responses of wild-type virus to lamivudine. Therefore two sets of analyses were performed, one 
including patient 3 and one excluding patient 3. 
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Results 
Twenty-one patients were analysed on a per protocol basis. Eleven patients received 150 mg 
lamivudine once daily for four weeks (group 1) and ten patients received 600 mg of 
lamivudine once daily for four weeks (group 2). Patients in the two groups were comparable 
with regard to age, sex, race and baseline viral load. Baseline serwn transaminase levels were 
not significantly different between the two groups, although a wider range in the higher dose 
group was observed. Two patients in group 1 and 1 patient in group 2 were negative for 
HBeAg at start of therapy; all other patients had detectable HBeAg at start of therapy. The 
majority of patients were treatment naYve (Table 1 ). In patients who were treated with 
lamivudine previously, the drug was withdrawn at least 10 months before start of this study 
(median: 18 months, range 10-44 months). None of these patients had detectable YMDD 
mutant virus in blood at start of therapy. HBV DNA and Body Mass Index (weight divided 
by the square of the length in meters) at baseline were not significantly different between the 
two treatment groups (Table 1 ). 
Table I Patient and pre-treatment characteristics 
Treatment group 
Male/female 
Age (median, range) 
Race 
Caucasian 
Asian 
Other 
Previous therapy 
Lamivudine 
Alpha interferon 
Lamivudine!alpha interferon 
None 
Body Mass Index (median,range) 
Cirrhosis 
ALT (lUll) (median,range) 
HBV DNA (geq/ml; median, 
range) 
Upper Limit of Normal is 30 lUll. 
150 mg lamivudine 
9/2 
27 years (! 8-51) 
2 
5 
4 
2 
2 
6 
24.1 kgim2 (18.3-30.7) 
1 
47 (19-113) 
7.9xl 08 (2.8xl 07-1.3xl 010) 
600 mg lamivudine 
9/1 
32 years (18-51) 
5 
2 
3 
3 
2 
I 
4 
22.4 kg/m2 (19.4-30.0) 
0 
90 (18-645) 
1.5xl09 (8.5xl07-7.6xlO') 
Patient 3, who had a rebound after an initial viral decline had not received lamivudine 
previously. Results obtained from the analyses with and without patient 3 were similar. Data 
without patient 3 are not shown. The mean viral decline in group 1 and 2 is shown in Figure 1. 
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Fig I Mean HBV DNA decline on a log scale in group I (circles) and group 2 (squares) 
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Both the exponential bi-phasic model as well as the piecewise linear regression model fitted the 
observed HBV DNA data equally well, as observed by visual assessment (Figure 2) and 
expressed by a comparable AIC (-220 versus -243) (Table 2). 
Fig 2 Representation of viral decline by means of a statistical fit of the two dose groups with 
the hi-phasic model and the piecewise linear model. Both fits practically overlap one 
another. 
Straight black line: 600 mg, piecewise linear fit 
Dotted grey line: 600 mg, hi-phasic fit 
Dotted black line: 150 mg, piecewise linear fit 
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Comparison of the dynamical parameters between the two doses 
The group-v.rise fit as well as the individual fit indicated a greater effectiveness in blocking 
viral production (B) (Table 2 and Figure 3) and a shorter half-life of infected cells if a higher 
dose is applied (0.96 versus 0.92; p=0.028 and 125 hours versus 186 hours; p=0.030 
respectively). Piecewise linear modeling showed similar results with a first phase of viral 
decline of 0.44 log/day for group 1 and 0.56 log/day for group 2 (p=0.064). This resembles a 
half-life of free virus of 13 hours in both treatment groups. Viral decline during the second 
phase was 0.041 log/day in group 1 and 0.063 log/day in group 2; i.e. a half life of infected 
hepatocytes of 174 hours in group 1 and 116 hours in group 2 (p=0.035). The break point of 
viral decline was calculated to be at 2.26 days in group 1 and 2.34 days in group 2 which was 
not significantly different. 
Fig 3 Effectiveness of lamivudine m blocking viral production in relation to dose and 
previous lamivudine therapy. 
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Comparison of the dynamical parameters in relation to baseline factors 
Baseline AL T was significantly related to the slope of the second phase: a higher AL T showed 
a faster decline (0.139 versus 0.095, p=0.03, including patient 3 and 0.155 versus 0.098, 
p=O.OOl, excluding patient 3). To support these findings, comparison of the point estimate of 
the per patient separate non-linear fit of the exponential bi-phasic model showed that A-2 and 0 
were significantly higher for patients with ALT>2xULN (Mann-Whitney test; p=0.04, 
including patient 3 and p=0.03, excluding patient 3). However, if extending the model with 
dose, the baseline ALT was no longer significantly related to the slope of the second phase 
(p=O.l8). Moreover, the difference between the two dose groups after correcting for ALT 
became less pronounced; a difference of 0.039 (p=O.ll) versus a difference of 0.144-
0.095=0.049 (p=0.035)(Table 2, i.e. including patient 3). This implies a possible correlation 
between the effect of dose and the baseline ALT. 
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Patients who were previously treated with lamivudine showed a trend to a slower initial viral 
decline compared to lamivudine-nalve patients (0.942 versus 1.257, p=0.06). Applying the 
Mann-VVhitney test of the point estimate for c gave similar results, p=0.04 (including patient 3). 
After extending the model with dose, this difference even became significant (p~O.OOO 1 ). 
Body Mass Index and race were not related to any of the parameters calculated. Differences 
between sexes were not evaluated because only 3/21 patients were women. 
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Table 2 Parameter estimates based on the hi-phasic model and the piecewise linear regression model with mixed effect group fitting; 
population average with the range of individual patients. 
ISO mg/day mean fit 600 mg/day mean fit AIC p-value (F-test) 
Bi-phasic model: 
V0 (Ae'·I '+(l-A)e1'2') 
In (Vo) 
c (with fixed delay of6 hours) 
0 (iffJ~1) 
lc, (ift]~O) 
e (with fixed delay of6 hours) 
half-life offi·ee vims 
half-life of infected hepatocytes 
Piecewise linear regression model: 
log(V ( t) )~a+ b *t+c, *( t -tb) * ( t>tb) 
In (Vo) 
b 
b+c, 
Tb (days) 
half-life offi·ee virus 
half-life of infected hepatocytes 
Vo =initial viral load 
c =clearance rate of free virus 
20.00 (range 16.26-23.18) 
1.13 (range 0.77-1.76) 
0.089 (range -0.03-0.19) 
0.081 (range -0.03-0.18) 
92% (range 84-97) 
15 In~ (range 9-22) 
186 hrs ( ~8 days)(range -516-331) 
20.69 (range 17.77-22.87) 
1.34 (range 0.92-1.85) 
0.133 (range 0.08-0.21) 
0.127 (range 0.08-0.19) 
96% (range 92-99.8) 
12 hrs (range 9-18) 
125 hrs c~s days)(range 79-210) 
20.04 (rangel6.26-23.22) 20.75 (range 17.85-22.88) 
LO I (range 0.70-1.32) 1.31 (range 0.82- LSI) 
0.095 (range -0.04-0.20) 0.144 (range 0.08-0.20) 
2.26 (rangeL53-2.71) 2.34 (range 1.99-2.58) 
13 hrs (rangel3-24) 13 hrs (range 9-20) 
174 hrs (~7 days)(range -275-430) 116 hrs c~ 5 days)(range 82-205) 
o ~death rate of productively infected cells 
c =effectiveness oflamivudine in blocking virion production 
ll =effectiveness oflamivudine in blocking de novo infection ofuninfected cells 
a ~IogV(t=O) 
b ~slope oftirst phase 
b+c2 =slope of second phase 
tb =breaking point 
-220 
-243 
0.438 
0.257 
0.030 
0.030 
0.028 
0.257 
0.030 
0.429 
0.064 
O.Q35 
0.644 
0.064 
O.Q35 
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Discussion 
Viral decline during nucleoside analogue therapy for HBV consists of an initial phase of 
elimination of free virus and a second phase of the death rate of infected cells. Since 
infectious particles are also lost during cell division, 8 probably reflects both cell death and 
division. Both the hi-phasic model and the piecewise linear model provide similar parameters, 
which describe the several biological processes that take place during the first weeks of 
antiviral therapy. 
Modeling of the HBV DNA data resulted in a significantly steeper slope of viral decline during 
the second phase (8 or lambda 2 in the bi-phasic model and b+c in the piecewise linear model) 
for the higher dose group. Lambda 2 is a variable dependent on 0, 11, E and to a lesser extent c, 
which indicates that several factors might be responsible for the difference between the two 
doses. Biologically, 0 can not be influenced by lamivudine because this drug has no hepatotoxic 
properties. However, if baseline AL T was accounted for, the initial difference in viral decline 
between the dose groups during the second phase seemed to disappear. This could indicate that 
0, more than c, 11 and e, was responsible for the faster viral decline in the second phase in group 
2. Previous studies have shovm that HBeAg seroconversion occurs significantly more often in 
those patients with elevated baseline ALT (13) compared to immunotolerant patients with 
normal AL T levels. This indicates that higher turnover of infected hepatocytes is followed by a 
faster occurrence of HBeAg seroconversion. However, it needs to be evaluated yet whether 
HBeAg seroconversion during lamivudine therapy is durable after withdrawal of therapy 
(19,20) and whether patients with higher baseline ALT are capable of developing a more 
durable HBeAg seroconversion. Based on our present lmowledge, the primary action of 
lamivudine is inhibition of viral replication (21 ). One study reports on restoration of HBV-
specific T -cells during lamivudine therapy in patients with hyporesponsive T -cells during active 
viral replication (22). However, this effect seemed to be induced through suppression of viral 
replication and not by lamivudine itself. 
The defmition of non-response to lamivudine is not unequivocal. Both continuing active viral 
replication after several months of therapy as well as breakthrough of variant HBV may be 
considered as a failing response. However, these responses to lamivudine are based on different 
mechanisms. Patients who have shovm continuing active viral replication during previous 
lamivudine therapy without the development of variant virus may be less capable of optimal 
absorption, uptake in hepatocytes or phosphorylation in the hepatocyte (23). These are all host 
specific factors, which will probably be similar if lamivudine is applied again. Secondly, 
patients who have developed lamivudine resistance and who are withdrawn from therapy show 
a gradual return of wild-type virus. It has been described that lamivudine resistant virus was still 
detectable 4 months after withdrawal of therapy (24). Due to the limitations in the detection 
level of the tests use~ absence of variant virus does not necessarily mean that it is not present in 
the viral population. With the INNO-LiPA DR-PCR-based assay, as few as I 03 copies of 
mutant virus per ml and 4-8% of mutant virus in a population of wildtype virus can be detected 
(25). This could mean that our previously lamivudine treated patients indeed were still infected 
with mutant virus even though it cannot be detected. If variant virus was still present, 
reintroduction of lamivudine could cause renewed replication of the variant virus resulting in 
decreased decline of viral replication within the first few weeks of therapy. Lastly, selection of 
patients could also be an important factor for induction of the difference between previously 
lamivudine treated patients and lamivudine naYve patients. Further studies are needed to explore 
these findings. 
Body Mass Index and race were not related to any of the parameters that were calculated in the 
model. Larnivudine is a hydrophilic compound that is not stored in fat after absorption (26). 
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Therefore, it seems reasonable to assume that both patients with a low and high body mass 
index respond similarly to lamiwdine therapy. Race did not influence the response to therapy 
but is probably partially related to immune tolerant or active status as reflected by serum 
transaminases. 
In our study with a high frequency of sampling during the first week of therapy the different 
response to different doses oflamivudine can be described in detail by both the hi-phasic model 
and the piecewise linear model. Higher intrinsic activity against HBV is related to a higher 
turnover of infected cells regardless of the dose of lamiwdine. Previous non-response to 
lamivudine therapy seemed to have a negative effect on re-introduction of lamivudine. 
Therefore, re-institution of lamivudine should probably only occur if the clinical situation 
requires an intervention, e.g. in the case of flares of serum transaminases caused by HBV. 
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Chapter 4 
Summary 
Lamivudine has recently been registered for the treatment of chronic hepatitis B patients. The 
main therapeutic outcome in the studies on which the registration was based, was a drop of 
HBV DNA below the level of detection of the insensitive Abbott assay. However. as reported 
previously by us, with the use of sensitive assays, individual differences in virologic response 
to lamivudine can be detected. 
To analyse the chain of events after oral intake of lamivudine until the conversion to the 
active tri-phosphate, we modified and validated a High Pressure Liquid Chromatography 
(HPLC) method to evaluate lamivudine plasma levels. Lamivudine levels in chronic hepatitis 
B patients who participated in a study on the efficacy of lamivudine were comparable to our 
reference curve which was derived from 8 chronic hepatitis B patients. However, lamivudine 
exerts its action as the active tri-phosphate inside the hepatocyte after extensive handling. 
Therefore, additional steps in the pharmacokinetic process should be evaluated to explore the 
actual mechanisms that are responsible for the suboptimal response to lamivudine in a number 
of patients. 
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Introduction 
Lamivudine, the negative enantiomer of2'-3' deoxy 3' thiacytidine, is a nucleoside analogue 
which has recently been registered for the treatment of chronically infected hepatitis B 
patients. In large phase III studies the favourable effect of this drug was shown on suppression 
of HBV DNA -a parameter expressing active viral replication- that is often followed by a 
decline oftransaminases and improvement of liver histology (1-3). The conclusions in these 
studies were based on the percentage of patients with a viral decline below the lower limit 
(approximately 107 genome equivalents/ml (geq/ml)) of the insensitive liquid hybridisation 
assays (Abbott Genostics, Abbott Laboratories, Abbott Park, IL). HBV DNA became 
undetectable in around 80% of patients as measured with this test after 6 months of therapy 
(1). However, if we look more carefully applying more sensitive assays, individual 
differences in response to lamivudine become apparent ( 4, 5). Whereas some patients show a 
rapid decline to levels even below the threshold of the qualitative PCR assay (Roche Monitor, 
lower limit of detection 400 geq/ml), in others, the hepatitis B virus (HBV) continues to 
replicate actively even after 6 months of therapy. We previously reported on a cohort oflong-
term lamivudine treated chronic hepatitis B patients in Rotterdam (4). In !9 patients with still 
detectable HBV DNA by insensitive assays (Digene, liquid hybridisation assay, lower limit of 
detection !,5xl06 geq/ml) after six months of therapy, only three patients had a mutant virus 
which could explain this continuing active viral replication. Thus, ongoing active replication 
of the HBV must be based on some other phenomenon in the majority of patients. 
Lamivudine is subject to several transport and activation steps from oral intake until 
incorporation into the pregenomic viral chain. Our hypothesis was that unfavourable transport 
and activation oflamivudine might be responsible for the suboptimal decline ofHBV DNA in 
some patients. Therefore, we studied in chronic hepatitis B patients the availability of 
lamivudine in blood after a standard oral dose. With these data we have a tool to exclude a 
problem in the first step of the pharmacokinetic process. 
Methods and Patients 
Methods 
Group A. Eight patients were evaluated for 24 hours after oral intake of a single dose of 
lamivudine 150 mg in order to obtain a lamivudine plasma reference curve. Patients fasted 
overnight and blood was withdrawn during 24 hours at t=O, !5, 30, 45, 60 and 90 minutes and 
2, 3, 4, 6, 8, !2, !8 and 24 hours after intake oflamivudine. 
Group B. In a group of nine patients in which the viral decline during lamivudine 150 mg 
therapy (6) was studied in detail, the lamivudine concentration in a serum sample taken 6 
hours after start of lamivudine therapy was assessed. The pharmacokinetic reference curve 
was based on plasma samples. Therefore, the agreement between plasma and serum results 
was ascertained in 9 randomly selected patients on lamivudine who visited the outpatient 
clinic (group C). 
High Pressure Liquid Chromatography (HPLC) ofLamivudine in Plasma and Serum 
Lamivudine in plasma and serum was assayed with a HPLC-method slightly modified from 
Harker eta!. (7). In short, the following procedure was used. 
Sample extraction is performed using a solid phase extraction method (Bond Elute Verify 
LRC; !0 cc/!30 mg, Varian Inc., Harbor City, CA, USA), after activation of the column with 
subsequently 2 ml of methanol and 2 ml of acetic acid I%. Next, a mixture of I ml of plasma 
and 1 ml of acetic acid 1% is applied to the column with a pressure of 5 mm Hg for at least 2 
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min. The column is consecutively washed and dried with distilled water, methanoVacetic acid 
10% (9: 1) and distilled water again. Desorption is carried out four times with 0.5 ml of 
methanol I ammonia 25% (9:1) under a low vacuum. The four fractions are collected and 
evaporated to dryness with a gentle flow of nitrogen at 40 °C and subsequently suspended in 
300 ul of the mobile phase by vortex-mixing. Separation of the mixture is performed by 
HLPC, equipped with a BDS Hypersil CIS column (250 x 4.6 mm ID: 5 urn), using a mixture 
of methanol (40 ml), acetonitrile (5 ml), glacial acetic acid (0.5 ml) and 0.1 M ammonium 
acetate in water ( 455 ml) as the mobile phase at a flow of 1 mVmin and at a temperature of 40 
°C. Quantification was based on UV -detection at 270 run, calibrated with a range of external 
standards in plasma, that were processed the same way. 
Intra- and inter-assay variability 
Eight calibration standards of lamivudine with a concentration ranging from 0.1 mg/l to 7.5 
mg/l were analysed simultaneously six times (intra-assay variability) expressed as the average 
accuracy with percent of the deviation from the nominal concentration; the procedure was 
repeated on three separate days (inter-assay variability) expressed as a coefficient of variation. 
Correlation between lamivudine levels in plasma and serum 
The concentrations of lamivudine in serum and plasma were compared by means of a linear 
plot as well as a Bland and Altman plot (8). 
Modeling of pharmacokinetic data 
From the 24 hours phannacokinetic curves, the average area under the curve (AUC), the half-
life oflamivudine (t'lS:), tma." and Cmax were calculated. Lamivudine concentrations were fitted 
with the TOPFIT pharmacokinetic program (9) using a 1-, 2- and 3-compartment model using 
four weightings (!, 11-.fy, 1/y and 1/y'). The Akaike criterion (10) was used to establish the 
best fit of our data. 
Results 
Patient characteristics of group A, B and C are shown in table 1. In group A, a considerable 
part of patients were in an advanced stage of liver-disease as indicated by decompensated 
liver cirrhosis. 
Table I Patient characteristics 
Age (median;range) 
Male/female 
Cirrhosis 
Additional 
medication 
Group A (n~S) 
37 (17-60) 
711 
4 
pt 3: ferrofumarate 
pt 5: furosemide, 
aldactone 
pt 7: methotrexate 
pt 8: data missing 
Group B (n~9) 
28 (22-51) 
7/2 
1 
pt 4: oral 
contraceptive 
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Group C (n-9) 
29 (17-57) 
6/3 
0 (n~S) 
pt I: pantozole 
pt 3: clinoril, cough-
medicine, doxazosine, 
losartan, atorvastatine, 
insuline 
t 4/9: aracetamol 
Lamivudine plasma levels 
The lower limit of detection of the HPLC-assay was determined at 0.005 mg/1 and the lower 
limit of quantification at 0.1 mg/1. The higher limit of detection was arbitrarily determined at 
7.5 mg/1. All calibration curves were linear betvveen 0.1-7.5 mg/1 with a variance betvveen-
15% to + 10% in this range. A variety of drugs, which were co-administered frequently to 
these patients, did not interfere with the extraction and detection procedure. 
The intra-assay variability showed an accuracy of 80-95% which is comparable with data 
described in the literature (7). The inter-assay variability was concentration dependent, 3-
16.6% (Table 2). Recovery of lamivudine in spiked plasma samples compared with non-
processed standard solutions was approximately 80%. 
The relation betvveen the concentration of lamivudine in plasma and serum was linear as 
observed by a line with a slope of 0.997 and an intercept at (0,0). The Bland and Altman plot 
showed a mean of the difference between the serum- and plasma- level of 0.02 mg/1 (s.d. ± 
0.0411). 
Table 2 Intra-assay and inter-assay variability. 
Intra-assa2:: variabili!Y Inter-assa~ variabili!2:: 
Theoretical Mean Standard %Coefficient Mean Standard %Coefficient 
value (n=6) deviation of variation (n=6) deviation of variation 
mg/1 
0.1 0.096 0.009 9.4 0.094 0.016 16.6 
0.21 0.189 0.009 4.8 0.19 0.018 10 
0.56 0.495 0.022 4.4 0.487 0.026 5.4 
1.04 0.875 0.013 1.5 0.882 0.043 4.9 
1.53 1.293 0.018 1.4 1.296 0.05 3.9 
2.18 1.819 0.11 6 1.884 0.102 5.4 
3.24 2.583 0.037 1.4 2.69 0.13 5 
7.5 6.177 0.18 2.9 6.22 0.18 3 
For group A, a mean AUC of 4994 mcg/l.h (s.d. 1524), a mean tm..., of 42 minutes (s.d. II) and a 
mean ern,, of 1.9 mg/1 (s.d. 0.70) were calculated (Fig 1). 
If we compare the 6 hours serum concentration of lamivudine in group B (median 0.35 mg/1; 
range 0.28-0.52) with the same time point in group A (median 0.32 mg/1; range 0.15-0.48) these 
concentrations are within the same range. 
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Fig 1 Pharmacokinetic reference curve (± 2xs.d.) based on 8 chronic hepatitis B patients 
treated with lamivudine 150 mg. once daily (group A). 
Time in minutes 
Discussion 
If the inhibitory effect of lamivudine on HBV replication is studied with a sensitive assay 
with a dynamic range between 400-109 geq/ml, a wide variation in response between 
individual patients is observed. In a previous study, we showed that this could only in part be 
explained by the emergence of a mutation in the catalytic site of the polymerase gene of the 
hepatitis B virus ( 4). In this study we made a first step in further exploration of other 
mechanisms which might explain the variability of response to lamivudine. 
The pharmacokinetic process of any drug, including lamivudine, is characterised by a 
sequence of events: absorption, distribution, metabolism and elimination. Lamivudine is 
highly soluble. dissolves rapidly once in the stomach and is being absorbed in the small 
intestine by passive diffusion. Food reduces the rate of absorption but not the extent: tma.x is 
prolonged, Cma.x is reduced and the AUC is not altered (11). The absolute hie-availability is 
reported to be around 80% with a mean volume of distribution of 1.3 l!kg, indicating 
considerable distribution into deeper tissues (12). In chronic hepatitis B patients, lamivudine 
acts in the liver, the target organ for viral replication. Lamivudine probably enters hepatocytes 
through active uptake by pyrimidine nucleoside transporters (13,14). In the cytoplasm of the 
hepatocyte, lamivudine is phosphorylated to the mono-, di- and triphosphate by deoxycytidine 
kinase, cytidine monophosphate kinase and pyrimidine nucleoside diphosphate kinase 
respectively. The diphosphate is present in highest concentrations inside the hepatocyte and 
the conversion of the di-phosphate to the tri-phophate is the rate-limiting step (15). This 
extensive bio-activation makes the drug prone to individual differences between patients. 
Only 5-10% of lamivudine is metabolised to a trans-sulphoxide metabolite and excreted in 
urine, around 70% of the drug is excreted unchanged in urine (16). 
In this study, we modified and validated the HPLC assay for detection of lamivudine in 
plasma. Only few data on pharmacokinetics of lamivudine in compensated chronic hepatitis B 
patients have been published (!6). Our pharmacokinetic parameters are comparable to the 
published data. Measurement of levels of lamivudine in daily practice may be useful for two 
purposes. If the level is within the normal range, this ascertains that patients have been 
compliant with therapy on the one hand and that on the other hand absorption, the fust 
pharmacokinetic step, is adequate. 
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As can be observed from our data, levels of lamivudine in plasma 6 hours after intake of 
lamivudine (group B) are in the same range of patients in group A at 6 hours. These data 
however, should be interpreted with caution, since group characteristics vary. Recent studies 
have stressed the potential influence of co-administered drugs on lamivudine kinetics. This is 
either caused by the increase of phosphorylation of lamivudine (e.g. hydroxyurea, 
methotrexate) (17) or because of reduction of the excretion ratio of lamivudine in urine (e.g. 
trimethoprim) (18). 
Our kinetic data show that the lamivudine concentrations in group B are well above the in 
vitro ICso (16) even 5 hours after the maximum concentration in plasma has been reached. 
These data also show that all patients have been compliant and that absorption was adequate. 
Plasma levels have been measured after intake of the first dose oflarnivudine but these levels 
may change during long-term therapy. Previous data do not indicate that lamivudine 
accumulates during long-term application, but these data ascertain sufficient levels of 
lamivudine above the in vitro !C50 throughout the 24-hour period (16). In contrast. in 7 out of 
8 patients of group A in our study levels of larnivudine 24 hours after intake are undetectable. 
This could necessitate re-opening of the discussion on twice daily dosing. However, this may 
not even be an issue, since we feel that more focus should be put on levels of lamivudine-
phosphates inside hepatocytes. Half-life of lamivudine tri-phosphate in human lymphocytes 
infected with the Human Immunodeficiency Virus (HIV) have been calculated to be 
substantially longer (10.5-15.5 hours) than lamivudine itself in serum (19). Conflicting data 
on the half-life oflamivudine-triphosphate in hepatocytes have been published (3.6-8 hours in 
primary duck hepatocytes (20) versus 17-19 hours in HepG2 cell lines (16)). Therefore, 
research into human hepatocytes is needed both to address the dosing issue, as well as to 
better understand the differences between individual patients. 
Absorption of lamivudine is a passive process and may therefore be the least important reason 
for variation in response to lamivudine between patients. In contrast, uptake of lamivudine in 
hepatocytes is most likely an active process, and lamivudine is phosphorylated inside 
hepatocytes. Phosphorylation is mediated by host enzymes and the efficacy of the process 
from parent drug to active tri-phosphate and persistence of the active tri-phosphate in the 
hepatocyte may vary between individual patients due to genetic polymorphism. Therefore, in 
order to be able to explain differences in viral decline between patients, further exploration 
into the patient to patient differences is needed. 
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Chapter 5A 
Summary 
A large percentage ofHIV-1 infected patients have serological evidence of a past or present 
HBV infection,. Long-term survival is increasing for HIV-patients because of highly active 
antiretroviral therapy. Therefore, the chronic hepatitis B infection may become an important 
determinant of disease outcome in these co-infected patients. 
We describe tvvo HIV/HBV co-infected patients who were treated with extended antiviral 
therapy, initially indicated for the HIV infection. Lamivudine, a suppresser of viral replication 
in both infections, was one of these antiviral drugs. One patient showed a severe rebound of 
the HBV after withdrawal of larnivudine, the other patient developed a mutant hepatitis B 
virus after 18 months of treatment. This mutation was exclusively induced by lamivudine. 
These patients show that, with improved HIV -related survival, the HBV infection should be 
monitored carefully, thereby enabling the physician to interfere with therapy when necessary. 
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Introduction 
About 80% of Human Immunodeficiency Virus (HIV)-1 positive patients have serological 
evidence of past or present hepatitis B virus (HBV) infection (I). With the introduction of 
triple therapy for HIV -I infected patients and the expectation of markedly prolonged survival, 
the consequences of chronic HBV infection in HIV -1 infected patients are becoming 
clinically relevant and a determinant of survival. 
Lamivudine, the(-) enantiomer of2'-deoxy-3'-thiacytidine, is virus suppressive in both HIV-1 
infection and HBV infection (2,3). In addition, antiretroviral therapy may restore immunity 
through suppression of HIV-1 RNA and repopulation of the immune system. This adds to 
eradication of the HBV (4). Furthermore, nucleoside analogues used for HN-1 infections, 
have been reported to cause lactic acidosis and liver steatosis (5). Special attention should be 
paid to these associated effects in patients with manifest liver disease, especially cirrhosis, as 
hepatic failure might be prevented. 
Lamivudine can induce mutations in the YMDD motif of the HBV DNA polymerase gene in 
both HIV-1 and HBV (6-9). Withdrawal oflamivudine is usually followed by reactivation of 
HBV infection, detectable by rising HBV DNA levels. In some patients this surge of viral 
replication is followed by a hepatitis flare with elevated ALT levels (10). 
Based on our experience in two patients co-infected with HIV-1 and HBV, we would like to 
focus attention on two syndromes associated with the use or withdrawal of lamivudine. 
Case history 
Patient A, a 49-year old man, initially visited our clinic in March 1990. Routine laboratory 
testing before surgery revealed liver function disorders. Subsequently he was found to be 
HBsAg positive and HBeAg positive. In addition to the HBV infection a HIV -1 infection was 
diagnosed. On physical examination no major abnormalities were detected, except a genital 
herpes-infection. Laboratory testing showed: no abnormalities other than AST 41 U/1 (5-30 
U/1); ALT 81 U/1 (5-30 U/1) and CD4 cell count 0.46x!0911 (0.5-1.57x!09/l). Serum markers 
of HBV infection: HBsAg positive; anti-HBc positive; HBeAg positive; anti-HBs negative; 
anti-HBe negative (IMx, Abbott, Chicago, USA) and HBV DNA 2.56x!09 genome 
equivalents (geq)/ml (Eurohep standard (II), measured as 275 pg/ml in Genostics assay, 
Abbott, USA). Anti-hepatitis C virus (HCV) negative; anti-hepatitis D virus (HDV) negative; 
anti-cytomegalo virus (CMV) negative. A liver biopsy showed a chronic persistent hepatitis 
with mild periportal fibrosis. 
Because of a decline ofCD4 positive cells, AZT monotherapy was statted in February 1992. 
Larnivudine was added in December 1993 (Fig. I). During this treatment, the HBV infection 
became inactive according to non-detectable HBV DNA and HBeAg. The loss ofHBeAg was 
associated with a hepatitis flare. HIV -I RNA levels (Roche Monitor 1.0, Somerville, New 
Jersey, USA) however, remained high(> lx!04 geq/ml). In 1996, therapy was changed to 
stavudine, didanosine and indinavir triple therapy; lamivudine was withdrawn. HIV -1 RNA 
levels dropped markedly, even below detection levels, but stabilized around I 03 geq/ml. CD4 
cell counts increased from 0.16x10911 to above 0.2x109!1. Three months after discontinuation 
of larnivudine, HBV DNA rose to 3.7xl09 geq/ml (measured as 12.010 pg/ml in Digene 
assay, Murex, UK), accompanied by a rise of HBeAg. Five months after cessation of 
larnivudine, ALT had risen to more than 600 U/1. At this moment HBV DNA levels had 
become undetectable by liquid hybridization again after the reintroduction of larnivudine. 
This was followed by a rapid decrease to normal ALT levels in December 1996. At March 
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1998 the HBV infection was still suppressed (HBV DNA negative by PCR, HBeAg negative), 
and serum AL T normal. 
Fig 1 HIV-1 HBV co-infection. Patient A. The profound virus suppressive effect of 
lamivudine and the hepatitis episode associated with HBeAg loss after withdrawal of 
lamivudine is illustrated. 
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In March 1994, patient B, a 48-year old man was admitted to our hospital because of marked 
elevation ofhis liver enzymes. He was found to be HBV and HIV-1 positive. 
On physical examination no significant abnormalities were detected. Laboratory results were: 
platelets l02xl09/I (l40-360xl09/I); CD4 cell count 0.08xl09/I (0.5-l.57xl09/I); prothrombin 
time 13.0 seconds (9.3-12.3 seconds); bilirubin 20 lffilOl/1 (4-141J1llol/I); alkaline phosphatase 
84 U/1 (25-75 U/1); yGT 71 U/1 (5-35 Ull); AST 249 U/1 (5-30 U/1); ALT 295 U/1 (5-30 Ull); 
albumen 32 gil (36-48 gil); IgG 36.3 gil (8-18 gil); HBsAg positive; HBeAg positive; anti-
HBc positive; anti-HBe negative (!Mx, Abbott. Chicago, USA); HBV DNA 2.77xl09 geq/ml 
(measured as 277 pg/ml in Genostics assay, Abbott. USA); anti-hepatitis A virus (HA V) 
(IgM) positive; anti-HCV negative; anti-HDV negative; anti-HIV-1 positive. 
The liver biopsy showed cirrhosis, chronic moderate active hepatitis with lobular involvement 
and collapse. The ultrasound of the upper abdomen showed hepatosplenomegaly and ascites. 
Because of his low CD4 cell count, priority was given to HIV-1 therapy. Treatment was 
started with zidovudine 250 mg bd and co-trimaxol 480 mg od, half a year later lamivudine 
300 mg bd was added. The medication was tolerated well. 
During lamivudine therapy, HBV DNA fell below detection level in November 1994 (Fig. 2). 
HBeAg quantified with a Paul Ehrlich Standard, as reference and expressed in PEU (Units) 
declined from 487 PEU/ml to 0.9 PEU/ml in October 1995. HBe seroconversion did not 
occur. Concordant with the decline in virus levels, transaminase activity also declined to 
normal levels (below 30 U/1). 
One and a half years after starting larnivudine (mid 1996), while the patient was still taking 
larnivudine and zidovudine, a sudden rise in HBV DNA and HBeAg levels, followed by a rise 
of AL T to levels above 200 U/1 was documented. Sequencing of the YMDD motif of the C-
domain of the DNA polymerase of HBV showed a mutation at position 552 at which 
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methionine was replaced by valine, indicating lamivudine resistance. Lamivudine was 
continued as AL T levels had fallen spontaneously and there was fear of larnivudine 
withdrawal hepatitis in a patient with cirrhosis. Because of continued elevated levels ofHIV -1 
RNA up to 9xl 04 geq/ml, in October 1996 zidovudine was replaced by didanosine, stavudine, 
indinavir; the dose of lamivudine was reduced to 150 mg bd. Bilirubin rose markedly after the 
change in therapy which was attributed to interference of indinavir with the bilirubin 
metabolism; stable levels of prothrombin time. albumin and bile acids excluded progressive 
liver damage. ALT levels continued to fall and were back to normal at the beginning of 1997. 
The response of HIV-1 to the present medication is satisfactory with HIV-1 RNA below 
detection levels of quantitative PCR (<5.0x102 geq/ml), but only a marginal rise in CD4 cell 
count to 0,13xl09!1 was observed, An active HBV infection with levels ofHBV DNA up to 
l.Oxl09 geq/ml and HBeAg up to 4120 PEU/ml is still present, apparently without a 
detectable immune response. 
Fig 2 HIV -1 HBV co-infection. Patient B. The profound hepatitis B virus suppressive effect 
of lamivudine and the reappearance of HBV DNA (lamivudine resistance), followed 
by a hepatitis flare is illustrated, 
Chronic HBV infection does not influence the progression of HIV-1 to AIDS (1,12), In 
contrast, HIV-1 does influence the course of a HBV infection. Acute hepatitis B progresses to 
chronic hepatitis B in 5-10% of HIV -1 negative adults; in those who are positive for HIV -1 
the chronicity rate has been reported to be 40% (I), Chronic hepatitis B patients who are HIV-
1 infected have a less pronounced tendency to show a spontaneous decrease in viral 
replication than those who are HIV-1 negative (12,13). In addition, antiretroviral therapy can 
restore immunity and induce recovery from HBV (4). 
Our study shows that patients with HIV -1 HBV co-infection undergoing multiple treatments 
with nucleoside analogues can manifest hepatitis flares associated with drug induced 
resistance or with withdrawal. 
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A lamivudine withdrawal hepatitis flare, as seen in patient A, with AL T levels over ten times 
the upper limit of normal, occurs in 16% of immunocompetent patients. Usually these flares 
pass without clinically significant symptoms, in a minority of the patients jaundice is seen 
(14). Re-institution of lamivudine therapy reduces viral replication rapidly; simultaneously, 
the activated cytotoxic T cells can eliminate the remaining hepatocytes that express viral 
antigen. In our patient, suppressed viral replication with elevated immune response led to 
undetectable HBV DNA by PCR and loss ofHBeAg. 
Patient B became resistant to lamivudine reflected in a sudden rise of HBV DNA after 14 
months of treatment. In immunocompetent patients, resistance to lamivudine develops in 39% 
(actuarial cumulative incidence) at one year (7). In HIV-1 HBV co-infected patients, 
lamivudine resistance to HBV has not been described in the cohort of 40 patients with a 
progressive HIV -1 infection, co-infected with HBV treated with lamivudine for 12 months 
(15). Insensitivity of the HBV for lamivudine has been described in liver transplant recipients 
who showed a recurrence of viral replication starting after six months oflamivudine treatment 
(16-19). A mutation in the highly conserved YMDD motif of the reverse transcriptase gene is 
described to be the cause of the decreased sensitivity to this drug. In patient B, substitution of 
valine for methionine at position 552 of the Y1v1DD motif in the C-domain, which is explicitly 
linked to the leucine to methionine mutation at position 528 in the B-domain of the 
polymerase gene, was seen. After stopping lamivudine, the dominant virus population 
returned to the wild type, with accelerated viral replication and possible risk of hepatitis flare. 
With the increased efficacy of triple therapy causing prolonged survival of HIV -1 infected 
patients, HBV infection may become an important determinant of disease outcome in these 
patients. Overlap in therapy for these two viral infections should be monitored carefully since 
change in therapy because of non-response to lamivudine of one disease (HIV infection) 
might cause reactivation of the other (hepatitis B). 
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Chapter 5B 
Summary 
Introduction With the introduetion of HAART, the HIV-I has turned from a lethal into a 
chronic infection in the majority of patients. In homosexual populations, twenty percent of 
HIV-1 infected patients suffer from a chronic HBV infection, which may eventually lead to 
complications of the liver disease because of prolonged survival. Larnivudine is effective in 
reducing both HIV-1 and HBV viral replication. However, resistance for Iamivudine may 
complicate the course of the HBV disease in HIV-1-infected patients. We, therefore, 
conducted a retrospective study in HIV-1-HBV co-infected patients on lamivudine therapy. 
Patients and methods All HIV-1-HBV co-infected patients who were treated with lamivudine 
for over 6 months in 5 major referral clinics in the Netherlands with HBV DNA above 
2.0xl05 geq!ml at baseline, were evaluated. Retrospectively, the course of HBV DNA in 
available serum samples was established. If HBV DNA was detectable with the sensitive 
PCR-assay, Yl\1DD-analyses of the polymerase gene of the hepatitis B virus was executed 
with the INNO-LiPA-DR-strip. 
Results Forty-six patients were evaluated. The median level of HBV DNA at start of 
lamivudine therapy was 1.3lxl09 geq/ml (range 3.5x105-2.0x1010, n=43). Of three patients no 
baseline sample was available, but since HBV DNA was still above 2.0xl05 geq/ml at week 3, 
7 and 11, these patients were included. Median duration oflarnivudine therapy was 97 weeks 
(range 27-263). The percentage of detected mutations was 25% and 52% at one and two 
years, respectively. Twenty-two patients ultimately developed a mutation. Both baseline Body 
Mass Index and the decrease in CD4 cell count as a time dependent factor were significantly 
related to the emergence of mutations. In 10 out of 12 evaluated patients, HBV DNA levels 
returned to baseline level or even above baseline level after the development of mutant virus. 
One patient (5%) developed a flare of serum transaminases (ALT> !OxULN) 24 weeks after 
first detection of variant virus. 
Conclusion There is a linear time-dependent appearance of HBV mutations for lamivudine in 
our population. In a minority of patients (5%), development of a mutation was followed by a 
significant elevation of serum transarninases. A decline in CD4 cell count, which may 
indicate less response to HAART, induces a faster emergence of mutations. Close 
surveillance of HBV co-infected patients on therapy may be indicated due to the prolonged 
survival ofHIV-1 patients. 
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Introduction 
Both the Hepatitis B Virus (HBV) and the Human Immunodeficiency Virus-! (HIV-1) are 
transmitted similarly through sexual contact and blood-blood contact. Therefore, the majority of 
HIV-1 infected patients show serological evidence of a resolved or still present hepatitis B 
infection (I, 2), 
During the early years of the HIV -1 epidemic, antiretroviral therapy for the HIV -1 infection in 
HIV-1-HBV co-infected patients was given priority since this disease was the most important 
factor for sUIVival. However, since 1997 combination therapy of nucleoside analogues (most 
often including lamivudine) with protease inhibitors or non-nucleoside reverse transcriptase 
inhibitors (3, 4), Highly Active Anti-Retroviral Therapy (HAART) is standard of care, resulting 
in sustained decreases of plasma HIV-1 RNA levels and a decrease in mortality in a large 
proportion of patients. As a result, the chronic hepatitis B infection in these patients and its 
potential complications might become more prominent. 
Both HIV-1 and HBV use a virus specific polymerase which mediates reverse transcription. 
This polymerase incorporates lamivudine into the proviral chain and thereby induces chain 
termination, As a result, lamivudine is capable of inhibiting viral replication of both HIV-1 and 
HBV (5-9). However, lamivudine monotherapy can induce the emergence of a mutation in the 
catalytic site of the polymerase gene (YMDD), resulting in reduced viral suppression (10-15), 
The pattern of development of resistance for lamivudine in HBV is more gradual than in HIV- L 
Nevertheless, previous studies in immunocompetent chronic hepatitis B patients show a 
cumulative incidence of 14-39% at one year (8, 16) increasing to 38-60% at two years of 
therapy (17, 18), In HIV-1-HBV co-infected patients a different pattern might be observed 
because of a suppressed immune status as reflected by decreased levels of CD4 positive 
lymphocytes, 
We conducted a retrospective study in 5 major referral clinics in the Netherlands to investigate 
the emergence of resistance for lamivudine in HIV -1-HBV co-infected patients who were 
treated with HAART including lamivudine. 
Patients and methods 
Five major referral hospitals in the Netherlands participated in this study, Eligible patients 
were HIV -1-HBV co-infected patients with a proven chronic hepatitis B infection, as 
observed by HBsAg positivity in serum for more than six months or by HBsAg positivity, 
negativity for anti-HBc IgM antibodies combined with active viral replication. All patients 
had detectable HBV DNA with the Digene II hybrid capture plate assay and were treated with 
lamivudine 300 mg od for at least six months. 
All patients visiting the outpatient clinic and who were treated with lamivudine for at least 6 
months were evaluated from the first day of lamivudine therapy until the last available serum-
or plasma-sample while on treatment, or the last visit in 1999. HBV-DNA levels were 
assessed on a frequent basis. 
In this retrospective study, frozen samples were evaluated for a mutation in the polymerase 
gene of the HBV at one year if they expressed active viral replication of the HBV as measured 
by the quantitative PCR-assay, Patients in which HBV DNA levels were below 1000 geq/ml 
at yearly intervals were considered to have not developed a variant HBV strain. Of these 
patients no mutation analysis was performed because of the limited amount of virus present. 
If a mutation in the HBV polymerase was observed at I year or 2 years, additional analyses 
were performed retrogradually, 
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CD4 cell count and CDS cell count which were assessed within 6 months before start of 
lamivudine therapy were regarded as baseline values. Values of serum transaminases and 
bilirubin were considered baseline levels if obtained within three months before start of 
lamivudine therapy. Changes in CD4 cell count during therapy were documented. 
Virology 
HBV DNA was quantified with a Digene II Hybrid Capture plate (HCS) assay (with a limit of 
detection of2.0xl05 geq/ml). IfHBV DNA was below the limit of detection of the HCS, the 
viral load was assessed using the HBV Monitor assay (Roche Diagnostics, Almere, The 
Netherlands; lower limit of detection of 1000 geq/ml). Both assays were calibrated using the 
EUROHEP standard (19). IgM anti-HBc was performed with a Micro-particle Enzyme Immuno 
Assay (AxSYM, Abbott, Chicago, IL). 
HIV -1 RNA levels were determined at the different sites with a commercial assay with a lower 
limit of detection of 500 geq/ml or less. Antibodies to the hepatitis C virus (aHCV), antibodies 
to the hepatitis D virus (aHDV) and HDV RNA were determined as previously described (20). 
HCV RNA was detected with the Cobas Amplicor HCV RNA 2.0 assay (Roche Diagnostics, 
Almere, The Netherlands). 
A Line Probe Assay (INNO LiPA Drug Resistant (DR) HBV, Innogenetics N.V., Ghent, 
Belgium) was used to determine the sequential occurrence of HBV mutations for lamivudine. 
The procedure was performed essentially as described by Stuyver et al (21 ). HBV DNA was 
isolated from serum using the High Pure Viral Nucleic Acid kit (Roche Diagnostics). 
Statistics 
The Kaplan-Meier method was applied to calculate the observed percentage of occurrence of 
mutations. The Cox-regression analysis was used to investigate the independent effect of the 
baseline factors sex, route of transmission of both viral infections, country of birth, centre, 
age, HBV DNA viral load, HIV-1 RNA viral load, CD4 cell count, CDS cell count, CD4/CDS 
ratio, AL T in relation to the Upper Limit of Normal (ULN), AST in relation to the Upper 
Limit ofNormal (ULN), bilirubin and Body Mass Index (BMI) on the moment of occurrence 
of mutations. To study the effect of the changes in CD4 cell count during treatment on the 
occurrence of mutations, a Cox model with baseline CD4 cell count at baseline and changes 
of CD4 cell count per week as time dependent factor was used. Significance was defined as 
p<0.05. 
Results 
Patients 
Forty-six patients were included in this study (Table 1). Twenty-nine patients had proven 
HBsAg positivity in serum for more than 6 months. Fifteen patients, of whom no previous 
blood samples were available before the first detection ofHBsAg positivity, were negative for 
anti-HBc IgM while showing active viral replication. In one patient anti-HBc IgM status 
before start of therapy was not known, however, the HBV was still actively replicating more 
than six months later. Another patient was only weakly positive for anti-HBc IgM which is 
compatible with a chronic infection. Both patients were considered to be chronic hepatitis B 
patients. Patient characteristics are shown in table I. The median level of HBV DNA in 43 
patients before start oflarnivudine therapy (at a median of3 weeks (range 0-38 weeks) before 
start of therapy) was 1.3lxl09 geq/ml (range 3.5xl05- 2.0xl010 geq/ml). Of three patients, no 
serum samples were available before start of lamivudine therapy; since HBV DNA was still 
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over 2.0x105 geq/ml at 3, 7 and 11 weeks of lamivudine therapy, these patients were also 
included in the analysis. 
Table l Baseline characteristics (n=46) 
Age median (range) 
Sex (M:F) 
Race Caucasian 
African origin 
South-American origin 
Route of transmission Homosexual 
Heterosexual 
Intravenous drugs 
BMI (kg/m0) n=42 
HBV DNA (geq/ml, median; range) n=43 
HIV-1 RNA (geq!ml, median; range) n=35 
ALT (xULN, median; range) n=36 
ALT<ULN 
AST (xULN, median; range) n=4l 
AST<ULN 
Bilirubin (>ULN :<ULN) n=30 
CD4 cells (>200xl06:<200xl06) n=4l 
38 years (24-62) 
44:2 
33 (72%) 
6 (13%) 
7 (15%) 
33 (72%) 
ll (24%) 
2 (4%) 
21.8 (15.8-27.7) 
l.3lx 109 (3.5xl05-2.0x!010) 
7.76xl04 (80-2.58xl06 geq/ml) 
1.8 (l-10.6) 
n=S (22%) 
2.1 (l-9.6) 
n=!O (24%) 
5:25 
17:24 
At start oflarnivudine therapy (150 mg oflarnivudine twice daily), 23 patients (50%) started 
with a combination of up to four nucleoside analogues (zidovudine, didanosine, stavudine or 
zalcitabine) and one or two protease inhibitors (ritonavir, indinavir, nelfinavir or saquinavir); 
18 patients (39%) received a combination of two or three nucleoside analogues and a minority 
of patients (5; 11 %) received a combination of two or three nucleoside analogues and a non-
nucleoside reverse transcriptase inhibitor (NNRTI, nevirapine). Fifteen patients were pre-
treated with antiretroviral therapy at the moment of start of lamivudine therapy. Forty-three 
patients were negative for antibodies to the hepatitis C virus (aHCV). Two patients had 
detectable antibodies for HCV, however, these patients did not show active HCV replication 
as shown by HCV RNA PCR negativity. In one patient, HCV status was not known. Thirty-
nine patients had not been in contact with the hepatitis D virus (HDV) as shown by aHDV 
negativity. Five patients were positive for aHDV; in 3 of these patients HDV RNA was also 
positive. These patients were included in the analysis because they all exhibited active viral 
replication. The anti-HDV status was not known in 2 patients. 
The median duration of larnivudine therapy was 97 weeks (range 27-263). However, the 
median duration until the last observation of HBV DNA during larnivudine therapy was 91 
weeks (range 14-263). The median CD4 cell count at baseline was l20xl06 cells/~! (n=4l; 
range lxl06-720xl06 cells/~!). During therapy, 14 out of24 patients (58%) with a CD4 cell 
count below 200 cells/~! showed an increase of CD4 cells to above 200 cells/~!, indicating 
that l 0/40 (25%) patients had a CD4-cell count below 200 cells/~! throughout the study period. 
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Fig 1 Kaplan-Meier curve representing the observed occurrence of mutations in the 
polymerase gene ofHBV during lamivudine therapy. 
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During therapy, 13 patients became PCR negative; 18 patients still had actively replicating 
virus (HBV DNA detectable by PCR) but HBV DNA below baseline levels and 15 patients 
showed a rebound in viral replication after an initial decline, 2 of whom initially became PCR 
negative. In our population of 46 patients, the percentage of observed YIDD or YVDD 
mutations (a substitution of methionine for isoleucine or valine in the C domain of the HBV 
polymerase) against lamivudine was 25% (95% CI 12-38%) at one year and 52% (95% CI 35-
69%) at two years (Fig 1). These percentages are based on the duration oflamivudine therapy. 
Twenty-two patients (48%) developed a mutation. The first observation of a mutation was at 
14 weeks (median 88 weeks (95% CI 38-138 weeks)). In 10 out of 22 patients, the first 
observation of a mutation was a combination of either two mutants (YVDD and YIDD, n=2) 
or a combination of one or two mutants and wildtype virus (YVDD, YIDD, YMDD, n~8). In 
five patients who developed a mutation, we were capable of determining a pattern of 
consecutive mutations (Table 2). As can be observed from these data, all patients eventually 
developed a YVDD mutation, even though in patient 29, the YIDD mutation was still present 
aside the YVDD mutation at week 141. In 18/22 patients (82%), HBV DNA level was below 
or equal to baseline level at the moment of detection of a mutation. In 10118 patients of whom 
we had follow-up samples after the development of variant virus -but still on therapy-, 
hepatitis B viral load returned to baseline level (n~2) or higher than baseline level (n~8). Only 
1/22 (5%) patients developing a variant virus showed an increase of serum transaminases to 
levels over lOxULN detected 24 weeks after the frrst observation of the presence of mutant 
virus. This flare of serum transminases did not coincide with a distortion of liver functions as 
indicated by a normal prothrombin time (PT) and albumin. CD4 positive cell count at the time 
of the hepatitis flare was 440 cells/j.tl (normal range: 500-1700 cells/j.tl). 
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Table 2 Time dependent sequence of mutations in five patients 
Patient Initial mutation week Consecutive mutation week 
4 YIDDIYVDD 25 YVDD 42 
19 YMDD/YIDD 24 YMDD/YIDDIYVDD-> 58 
YVDD 
23 YMDDIY!DDIYV 45 YVDD 55 
DD 
29 YMDD/YIDDIYV 33 YIDDIYVDD 50 
DD 
30 YMDDIYVDD 43 YVDD 64 
Effect of baseline factors on the time of emergence of a mutation 
Sex, country of birth, route of transmission of the HBV and IDV~l, centre, age at baseline, 
baseline HBV DNA, HIV-1 RNA, ALT in relation to the ULN, ASTin relation to the ULN, 
CD4-cell count, CDS-cell count, ratio of CD4- to CDS- cells, bilirubin and BMI were tested 
to investigate a possible relation to the time of emergence of a mutation. The BMI was the 
only significant baseline factor related to the time of emergence of a mutation (p=0.02) with a 
relative risk of 1.23 (Table 3). Extending the model with other co variates next to the BMI did 
not result in any other significantly related factors. The change in CD4 cell count per week 
during therapy included as a time-dependent factor was significantly related to the time of 
emergence of mutations: a decrease of 10x106 cells/J.Ll per week results in a relative risk of 
1.29 (p=0.005) to develop a mutation (Table 3). In the multivariate analysis, including both 
baseline BMI and the time dependent decrease in CD4 cell count, these two covariates were 
independently related to the time of emergence of mutations. 
Table3 Relation of baseline factors to the time of emergence of a Iamivudine 
induced mutation by Cox univariate regression analysis 
Baseline factor Relative Risk 95% Confidence Interval 2:-value 
Age 1.02 0.96-l.OS 0.57 
HBVDNA 1.3 O.S6-1.96 0.22 
HIV-1 RNA 0.86 0.49-1.52 0.61 
CD4 cell count 0.75 0.30-l.S7 0.19 
CD4 cell count (>200xl06:<200xl06) 1.63 0.60-4.43 0.34 
CDS cell count 2.46 0.20-30.46 0.4S 
CD4/CDS ratio 0.42 0.49-3.64 0.43 
ALTxULN·I· 1.03 0.90-!.19 0.66 
ASTxULNi· !.10 0.90-1.34 0.35 
Bilirubin (<ULN' versus >ULN') 1.70 0.59-4.94 0.33 
Bodle Mass Index 1.23 1.03-1.46 0.02 
Time dependent analysis 
Decrease of CD4 cell count of 1.29 1.08-1.53 0.005 
10xl06 cells/week 
'I Upper Limit ofNormal 
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Discussion 
Mutations in the YJ\.1DD in the region of the C domain of the polymerase gene of the hepatitis B 
virus induce a less efficient incorporation of lamivudine in the proviral hepatitis B strand (22). 
In this study on HBV-HIV-1 co-infected patients, we observed a 25 and 52 percent occurrence 
of mutations at 1 and 2 years of lamivudine therapy, respectively. Since our study is a 
retrospective study and data were obtained from the available stored serum and plasma samples 
only, there might have been an underestimation of the actual occurrence of mutations in this 
patient group. Our data however, are in agreement v.rith reports on the emergence of mutations 
during lamivudine therapy in immunocompetent Caucasian chronic hepatitis B patients (16) and 
liver transplant recipients on immunosuppressive therapy (23-26). Also, a cohort of French 
HIV-1-HBV co-infected patients (27) and a subpopulation of patients participating in the 
CAESAR study (28) showed similar results (50% of mutations at two year). The former study 
has a smaller sample size than our study population and in the latter study, only those patients 
with an initial response to lamivudine were evaluated for the emergence of mutations. However, 
also those patients with less favourable response to lamivudine may develop variant virus, 
therefore we decided to include all patients who were started on lamivudine therapy. Moreover, 
both studies apply direct sequencing techniques for detection of 1amivudine resistance which is 
a less sensitive method than the InnoLiPA-DR-assay. With the sequencing technique, mutant 
virus can be detected if it accounts for more than 50% of the complete viral population whereas 
the InnoLiPA-DR-assay is capable of detecting only 5% of mutant virus v.rithin the mixed viral 
population. 
The prevalence of mutations in any viral genome, possibly leading to resistance to antiviral 
drugs, is dependent on many factors. The level of viral replication, the error rate of the 
polymerase, the antiviral activity of the drug and the turnover of infected cells seem to be the 
most important factors that influence the mutation rate. In untreated immunosuppressed HIV-1-
HBV co-infected patients, the response of the immune system on viral replication may be weak, 
reflected by high levels of hepatitis B replication in relation to less elevated serum 
transaminases. A small study in liver transplant patients with post-transplant recurrence ofHBV 
infection, showed that baseline levels of HBV DNA and AL T were two independent predictors 
for development of larnivudine resistance (29). Our data do not support this fmding: baseline 
HBV DNA and AL T were not related to the time of emergence of mutations. In contrast, a 
decrease in CD4 cell count as a time dependent factor results in a faster development of a HBV 
mutation. A decrease in the CD4 cell count could be related to less response to HAART which 
in turn could be caused by less response of the HIV-1 to the applied combination of antiviral 
drugs or a failing compliance. Both causes could result in a higher hepatitis B viral replication 
and faster development of HBV mutations due to a decreased immune system. Our finding 
could therefore be in agreement with the study by Borroughs et al. who describe a higher 
mutant growth rate in immunosuppressed liver transplant patients as compared to lamivudine 
treated immunocompetent patients (30). However, the mechanism on which faster viral 
replication in transplant patients may be based, is partly different from immunodeficient HIV -1-
HBV co-infected patients due to the direct stimulation of viral replication by 
immunosuppressive agents (31 ). In case of a failing compliance, the alternate application and 
withdrawal of lamivudine may also add to the faster occurrence of mutations. Whatever the 
cause of the decrease in CD4 positive lymphocytes, patients with an unfavourable response to 
HAART should be monitored carefully. 
In addition to the time dependent influence of the decrease ofCD4 cells to the faster emergence 
of mutations, the Bl\1I was found to be the only baseline factor predictive of the emergence of 
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mutations. Lamivudine exhibits a large volume of distribution (1.3 1/kg) which implies that 
lamivudine is transported to deeper tissues after absorption but it is not stored in fat (32). In a 
previous study in immunocompetent chronic hepatitis B patients, we observed that the level of 
lamivudine in plasma at day 1 of therapy was not related to viral decline during 4 months of 
lamivudine therapy (33). Since all patients in the present study received 300 mg of lamivudine, 
it should guarantee sufficient Iamivudine plasma concentrations to obtain adequate intracellular 
levels to suppress the HBV replication. The relation of the higher BMI to the faster occurrence 
of mutations does not seem to be easily explained. However, from our data, we hypothesise that 
patients with a higher BMI might benefit from higher doses oflamivudine, but this needs to be 
studied more extensively. 
Mutation analysis with the InnoLiP A~DR-assay is an elegant method for detection of YiviDD 
variants in the polymerase genome. Since already 5% of the variant in the total viral population 
can be detected, the method is suitable for early detection of the most common mutations in the 
polymerase genome of HBV. In five patients who developed a mutation, we analysed several 
sequential serum samples. All patients showed a shift from an initial YIDD to a YVDD 
mutation. This sequence of mutations has been observed previously (13, 34) and it indicates that 
the valine mutation, which is explicitly linked to a mutation in the B domain at position 528, is 
probably the more stable mutation of the two. 
In conclusion, in this HIV-1-HBV population in which patients have been treated with long-
term lamivudine therapy there seems to be an almost linear occurrence of mutations. New 
antiviral drugs like entecavir and adefovir dipivoxil may be an option for this resistant patient 
population. HIV-HBV patients with less response to HAART therapy should be monitored 
more closely for the occurrence of mutations than patients who do respond well to therapy. 
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Chapter 5C 
Standard Interferon alpha treatment is only efficacious in 33% of selected chronic hepatitis B 
patients (1 ). Therefore, there is a need for additional non-toxic therapies. Lamivudine is a 
potent antiviral drug which is able to suppress hepatitis B virus (HBV)-DNA in serum to 
undetectable levels (by liquid hybridization assay) in more than 80% of patients after 6 
months of treatment (2). If, however, HBeAg does not become negative, treatment with 
lamivudine has to be continued. After prolonged treatment, resistance will evolve in up to 
14% of the patients after I year (3). This is reflected in a rise in HBV-DNA and alanine 
aminotransferase (ALT) activity. In patients treated with larnivudine after liver 
transplantation, a point mutation in the YMDD-locus of the polymerase gene has been shown 
(4). 
Four chronic HBV patients were treated with larnivudine for a median time of 60 weeks (range 
30-86). They responded well and became HBV-DNA negative by liquid hybridization assay 
(Digene) within 4-!8 weeks. After a median period of 56 weeks (range 26-72) they relapsed, as 
shown by a sudden increase in HBV-DNA, followed by a rise in ALT levels. Sequencing of the 
YMDD-motif of the C-domain of the polymerase gene in two patients, revealed a mutation: 
methionine at position 552 was replaced by isoleucine (M552I). In two other patients, 
methionine was replaced by valine (M552V). Because of the increase in ALT and HBV-DNA, 
we decided to evaluate famciclovir 500 mg three times a day for 4 weeks, in addition to 
continued lamivudine therapy. Famciclovir is, like lamivudine, a nucleoside analogue which 
inhibits DNA-polymerase. One patient became HBV -DNA negative concomitant with 
famciclovir (Fig I). Three other patients showed a minimal decrease in HBV-DNA (O.l-0.4log). 
Two patients with M552V and one patient with M552I did not respond to famciclovir. Patients 
with the valine mutation at position 552 also have a second mutation at position 528 in the B-
region of the reverse transcriptase part of the polymerase gene in which leucine is replaced by 
methionine. A virus with this mutation has previously been described to be resistant to 
famciclovir (5). The coexistence of these two mutations might stabilize the DNA-polymerase 
configuration (6). Resequencing of the polymerase gene of the patient who was initially found 
to have an isoleucine mutation and who did not respond to famciclovir, again showed M552I. 
The hypothesis in re-evaluating this patient, is that the isoleucine mutation represents a 
transitional state in which the isoleucine mutation coexists next to the valine mutation in serum. 
This series of events has been described in HIV patients who developed resistance to 
lamivudine (7). The transitional state has also been reported in immunocompetent lamivudine-
resistant HBV patients, in whom YIDD is thought to be the temporal intermediate (6). 
However, the HBV -DNA peak seen in patients might also be the expression of a breal'ihrough 
caused by the M5521. The rise in HBV-DNA is followed by inflammation, reflected by a 
sudden rise in AL T, which resolves this viremic state. In this scenario, famciclovir is not 
responsible for the rapid decline in HBV-DNA. 
In conclusion, in one of two patients with a lamivudine-induced M552I mutation, a loss of 
HBV-DNA coincided with famciclovir therapy. No significant response to famciclovir was 
observed in two patients with a valine mutation at position 552. 
If addition of famciclovir therapy is considered in lamivudine~treated patients, we think this 
should only be done after analysis of the underlying mutation in the polymerase region ofHBV. 
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Fig 1 Response ofHBV-DNA and ALT to lamivudine therapy. In this patient, at week 90, a 
mutant M5521 was detected; the effect of famciclovir administration is shown in the 
graph. 
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Chapter 6 
Summary 
Prolonged nucleoside analogue therapy has proved to induce reduction of viral replication and 
normalization of serum transaminases in the majority of chronic hepatitis B patients. 
However, from a theoretical point of view, monotherapy with lamivudine (a cytosine 
nucleoside analogue) will probably not result in eradication of hepatitis B virus (HBV). 
Extended prolongation of lamivudine therapy would be needed to clear the virus from the 
liver. The occurrence of mutations in combination with continuing low-grade viral replication 
in a number of patients will prevent elimination of the virus from the liver. However, 
combination therapy with more than one nucleoside analogue could possibly overcome the 
disadvantages ofmonotherapy. 
In this study, we report on 12 patients who were evaluated by means of a mathematical model 
during lamivudine monotherapy, lamivudine-famciclovir and lamivudine-ganciclovir therapy. 
The parameters representing blocking viral production, tum-over of free virus and tum-over 
of infected hepatocytes were not different between the treatment groups. 
Although our study group is small, these combinations probably do not offer a major 
advantage over lamivudine monotherapy. Different combinations of nucleoside analogues 
need to be studied in order to obtain a major break-through for this treatment strategy. 
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Introduction 
Lamivudine monotherapy has proven to be of benefit for chronic hepatitis B patients. Its main 
action is reduction of viral replication followed by normalization of serum transaminases and 
improvement of liver histology in the majority of patients (1-3). Especially for patients with 
an activated immune system, as reflected by elevated serum transaminases above 2x the 
Upper Limit of Normal (ULN), the chance of HBeAg seroconversion is enhanced (2, 4, 5). 
However, a considerable proportion of the patients continue to exhibit active viral replication 
after several months oflamivudine monotherapy (6, 7). Less than optimum viral suppression 
results in a continuing relatively high turnover of virus with an enhanced chance of induction 
of genetic diversity of the virus. Studies on therapies for Human Immunodeficiency Virus 
(HIV) patients have indicated that combining several nucleoside analogues may be a good 
way to postpone or maybe even prevent the emergence of mutations (8, 9). Since HBV and 
HIV both replicate by means of a viral polymerase and nucleoside analogue monotherapy 
results in resistance sooner or later, eventual treatment strategies will probably resemble HIV 
strategies. 
In particular HBV patients who did not respond to previous lamivudine therapy may benefit 
from combination therapy with a compound with slightly different characteristics than 
lamivudine. Phosphorylation of different nucleoside analogues to the active nucleoside 
analogue tri-phosphate inside the hepatocyte is mediated by different enzymes (Fig 1). 
Moreover, tri-phosphates of different nucleoside analogues exhibit different mechanisms of 
action. Therefore, a combination regime may result in more pronounced suppression of viral 
replication, thus rapidly reducing the generation time of the virus and postponing or maybe 
even preventing the emergence of mutations. 
Fig 1 Lamivudine, famciclovir, and ganciclovir: uptake into hepatocytes and 
phosphorylation into thetri-phosphate. Famciclovir is de-acyty'lated and oxidized to 
penciclovir before uptake into the hepatocyte. 
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In this randomized study, we evaluated the potential of a combination of a cytosine 
nucleoside analogue with a guanine nucleoside analogue versus standard lamivudine therapy. 
For one month, patients received either lamivudine monotherapy or lamivudine-famciclovir 
or lamivudine-ganciclovir combination therapy. The effect of these combination therapies 
was evaluated by means of dynamic description of viral decay, as previously used for 
lamivudine monotherapy (l 0). 
Patients and methods 
Eligible patients included men and women over 18 years of age who had a chronic hepatitis B 
virus infection defined by a biopsy-proven chronic hepatitis B or HBsAg positivity for more 
than 6 months. HBV DNA had to be >1.5xl06 genome equivalents/ml (geq/ml). HBeAg status 
had to be stable as documented by HBeAg positivity or negativity for at least three months 
before the start of therapy. Inflammation of the liver had to be limited as expressed by serum 
transaminases below ten times the Upper Limit of Normal (ULN). Patients had to be negative 
for antibodies to the hepatitis C (HCV) or D virus (HDV) or the Human Immunodeficiency 
Virus (HIV). Patients with decompensated liver disease, liver diseases with other etiologies or 
other serious concomitant illnesses were excluded. The study was approved by the Medical 
Ethics Committee of the University Hospital Rotterdam. All patients had to give written 
informed consent. 
Twelve patients were stratified according to previous lamivudine therapy and then randomly 
assigned to receive either lamivudine monotherapy (150 mg od), lamivudine (150 mg od) 
combined with famciclovir (500 mg three times a day) or lamivudine (150 mg od) combined 
with ganciclovir (1000 mg three times a day) for 4 weeks. Randomization was computer-
generated and randomization labels were kept in sealed non-opaque randomization envelopes. 
All patients were screened for eligibility within four weeks before the start of treatment. 
Patients were admitted to the hospital for the first two days (day 0-2). Blood samples for 
detection ofHBV DNA were drawn at screening, baseline and at t=6, 12, 18, 24, 30, 36, 42 and 
48 hours. Subsequently, blood samples were obtained daily during the frrst week and on days 7, 
10, 14,21 and 28. Safety was assessed on a weekly basis. 
HBV DNA measurement 
HBV DNA was quantified with a Digene Hybrid Capture II tube liquid hybridization assay 
(calibrated on the EUROHEP standard (11)). If HBV DNA became undetectable with the 
Digene Hybrid Capture II tube liquid hybridization assay (limit of detection 2.0xl05 geq/ml) 
during lamivudine treatment, it was reassessed with the quantitative PCR (Roche, Amplicor 
Diagnostics, Almere, The Netherlands calibrated on the EUROHEP standard). This assay has a 
lower limit of detection of 1000 geq/ml. 
Modeling 
Viral decay was modeled with a bi-phasic model previously used to evaluate HCV patients on 
alpha interferon (12) and viral decay in HBV patients during nucleoside analogue therapy (10, 
13, 14). Patients were fitted individually, and then group medians were calculated. A 
significant difference in parameters between the three treatment anns was obtained if p<0.05. 
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Results 
Twelve patients were randomly assigned to one of the three treatment arms. Four patients 
received lamivudine monotherapy (group 1 ), two of these patients had previously been treated 
with lamivudine. Four patients were treated with lamivudine-ganciclovir combination therapy 
(group 2), three of whom had previously received lamivudine. In the third group, four patients 
were treated with lamivudine-famciclovir combination therapy (group 3), three of whom had 
previously been treated with lamivudine. Age at baseline was comparable between the three 
groups. The majority of patients were of Caucasian origin (Table 1). The median level ofHBV 
DNA was 1.13xl09 geq/ml (range 8.6xl07-4.0lxl09), 2.47xl09 geq/ml (range 9.98xl06-
l.lxl010) and 2.54xl09 geq/ml (range 9.49xl06-4.6xl09) for groups I, 2 and 3, respectively. 
There was no significant difference in HBV DNA level between the three groups. All patients 
were aHCV and aHDV -negative. Eleven patients were negative for HIV. One patient in group I 
was not tested for the presence of antibodies to HIV. Median level of ALT in relation to the 
Upper Limit of Normal (ULN) was 1.6 (range 1.1-1.9), 1.5 (range 1-3) and 1.1 (range 1-1.2) for 
groups 1, 2 and 3, respectively). No significant differences between groups existed. 
Table I Baseline characteristics 
Lamivudine Lamivudine- Lamivudine-
monotherapy ganciclovir famciclovir 
combination theraEY combination therapy 
Age 29 (21-56) 32 (25-41) 37 (22-47) 
(years; median;range) 
Race Caucasian 3 3 3 
Asian I 1 1 
Sex (M:F) 2:2 4:0 2:2 
Previous therapy with 2 3 3 
lamivudine 
Median HBV DNA 1.13xl09 2.47xl09 2.54xl09 
(geq/ml); range (8.6xl 07-4.0 lxl09) (9.98xl 06-l.lxl 010) (9.49xl06 -4.6xl09) 
Median ALT (xULN); 1.6 (1.1-1.9) 1.5 (1-3) 1.1 (1-1.2) 
range 
Absolute viral decay during 1 month of therapy was not significantly different between the 
three groups (2.34 log (range 1.45-3.69), 2.39 log (range 1.21-3.30) and 2.07 log (range 1.78-
2.28) for groups 1, 2 and 3 respectively. In two patients (1 in group 2 and 1 in group 3) 
normalization of serum transaminases occurred. Viral dynamic parameters did not reveal a 
difference in behavior between the three groups (Table 2). In the first phase of viral decay, 
which represents the turnover of free virus, there was a non-significant difference between the 
three groups; however, a somewhat faster turnover was found for the combination therapies (16 
hours for the lamivudine monotherapy versus 12 hours and 10 hours for lamivudine-ganciclovir 
and lamivudine-famciclovir, respectively). The turnover of infected hepatocytes was most 
pronounced in the lamivudine-ganciclovir-treated patients. Effectiveness in blocking viral 
production was lowest in the lamivudine-ganciclovir group and highest and most consistent in 
the lamivudine-famciclovir group with all patients exhibiting more than 94% blocking of viral 
production. 
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Table 2 Different parameters calculated with the bi-phasic model 
lnVo 
c 
€ 
0 
TY, first phase (ln2/c) 
TY, second phase (ln2/o) 
Larnivudine 
monothcrapy 
(median; range) 
19.43 ( 16.51-22.59) 
1.07 (0.96-1.93) 
0.93 (0.89-0.98) 
0.08 (0.3-0.12) 
16lus (9-17) 
220 hrs (~9 days) 
(144-628) 
Yo ~viral load at start of therapy 
c =turn-over rate of fi:ee vims 
Larnivudine-ganciclovir Lamivudine-famciclovir p-value 
combination therapy combination therapy 
(median; range) (median; range) 
18.76 ( 15.89-21. 78) 21.39 (20.62-21.99) 0.78 
1.34 (1.04-1.65) 1.62 (1.26-2.35) 0.60 
0.86 (0.80-0.91) 0.95 (0.94-0.96) 0.44 
0.19 (0.13-0.25) 0.10 (0.04-0.24) 0.50 
12hrs(I0-16) 10hrs(7-13) 0.60 
92 hrs (~4 days) 173 hrs (~7 days) 0.50 
(66-126) (70-397) 
£ =effectiveness of antiviral compound in blocking viral replication 
o ~death rate of infected hepatocytes 
TY, ~half life 
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All patients finished the four-week treatment period and none of the patients experienced a 
serious adverse event. Most frequently observed adverse events are presented in table 3; they 
were comparable in the three groups. 
Table 3 
Fatigue 
Headache 
Hey fever 
Discussion 
Most frequently observed side effects 
Lamivudine 
monotherapy 
Lamivudine-
ganciclovir 
combination therapy 
2 
0 
0 
Lamivudine-
famciclovir 
combination therapy 
2 
Lamivudine, a cytosine nucleoside analogue, is capable of interfering with the replication of 
the hepatitis B virus (HBV) by terminating either the negative or the positive proviral DNA-
chain (15). Famciclovir and ganciclovir, guanine nucleoside analogues, cause proviral chain 
termination as well as inhibition of priming, the first step in viral polymerase-mediated 
replication (16-20). Simultaneous interference with different steps of viral replication could 
enhance the suppression of viral replication. 
In this study, we describe a population of chronic hepatitis B patients with unfavorable 
baseline characteristics. First of all, the majority of patients had been treated with lamivudine 
previously. As we have shown in a previous dynamic study (21), re-treatment with 
lamivudine yields a less potent inhibition of viral replication in relation to that of lamivudine-
nalve patients. Moreover, all patients had baseline serum transaminases which were only 
slightly elevated. In large studies on lamivudine-treated patients, baseline AL T has proven to 
be significantly related to HBeAg seroconversion ( 4, 5). Viral dynamic parameters were not 
significantly different between the three groups. If we look at the data more carefully, there 
seem to be two trends. 
First of all, lamivudine-famciclovir combination therapy exhibited a stronger and more 
consistent pattern in blocking viral production than the other treatment arms. A previous study 
on viral dynamics in patients treated with lamivudine and lamivudine-famciclovir showed a 
significantly better effect of combination therapy as compared to lamivudine monotherapy 
(14). Some factors might be responsible for these differences. Although all patients in the 
study by Lau et al. were Asian -these patients often show less intrinsic activity against the 
HBV- mean serum transaminases were elevated in both groups. This is in contrast to our 
patients who all expressed only slightly elevated serum transaminases. In addition, the 
majority of patients in our study had been treated with lamivudine in the past; no data on 
previous therapy are mentioned in Lau's study. Lastly, modeling of viral decay is dependent 
on many assumptions. The hi-phasic model describes two phases of viral decay and therefore 
forces the HBV DNA levels to fit two slopes of viral decay. If the treatment period is longer, 
presumably the initial decline in viral replication will last longer and therefore greater 
effectiveness in blocking viral replication will be calculated. 
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The second striking result of our study is that the turnover of infected hepatocytes was much 
smaller in the lamivudine-ganciclovir group than in the other groups. An explanation for this 
observation remains speculative. Baseline AL T in this group, which could have an effect on 
the turnover of infected hepatocytes, was not significantly different from that in the other 
groups. Ganciclovir has a much stronger inhibitory effect on infected than on uninfected cells. 
But cells that express a high rate of DNA synthesis, such as hematopoietic progenitor cells, 
are more prone to interference and inhibition of ganciclovir (22). However, hepatocytes have 
a slow tum-over rate: it has been calculated that the half-life of infected hepatocytes is l 0-l 00 
days (23) and is even much longer for uninfected hepatocytes. Therefore, it does not seem 
very likely that ganciclovir has a direct cytotoxic effect on (un)infected hepatocytes. 
Our study, which describes only a small population of patients, does not reveal a difference 
between the treatment arms. However, in vitro data, which were the basis for our study, 
suggest otherwise. The combination oflamivudine and famciclovir shows a synergistic effect 
in inhibiting viral replication (24-26). Active uptake into the hepatocyte as well as 
phosphorylation inside the hepatocyte depends on distinct mechanisms for lamivudine on the 
one hand and ganciclovir and famciclovir on the other hand (Fig 1) (24). However, 
deoxycitidine kinase, which catalyzes the conversion of lamivudine to lamivudine-
monophosphate, is also capable of metabolizing other nucleoside analogue monophosphates 
(27). Moreover, one should realize that the situation as mimicked in cell culture systems 
cannot automatically be translated to the in vivo situation. These cell cultures provide 
homologous cell cultures and do not include the inter-subject diversity in metabolism, as can 
be observed in patients. Therefore, these studies in cell systems can only be used as an 
indicator of what to expect in in vivo situations. 
This study in a small group of patients does not show a difference in viral dynamic parameters 
between the different treatment groups. It should be taken into account that both patient 
characteristics and modeling approaches influence the results, which are obtained in different 
studies. Because of the minimal additive antiviral effect of the combinations evaluated in this 
study over lamivudine monotherapy and the potential toxicity of ganciclovir in particular, we 
do not recommend either one of the combinations. 
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Summary 
Entecavir is an oral antiviral drug with selective activity against hepatitis B virus (HBV). We 
conducted a randomized, placebo-controlled, dose-escalating study in patients with chronic 
hepatitis B infection in which we evaluated the efficacy and safety of entecavir given for 28 
days. Follow-up was 24 weeks. 
All doses of entecavir (0.05 mg, 0.1 mg, 0.5 mg and 1.0 mg) showed a pronounced suppression 
of replication of the HBV with a 2.21. 2.29, 2.81 and 2.55 mean log10 reduction of viral load, 
respectively. Approximately 25% of patients on entecavir showed a decline of HBV DNA 
below the limit of detection of the Chiron HBV-DNA assay (<0.7 MEq/ml). ln the post-
dosing follow-up period patients who were treated with 0.5 and 1.0 mg of entecavir showed a 
considerably slower return in their HBV DNA levels to baseline compared with those patients 
treated with lower dosages (p<0.05). All doses of entecavir were well tolerated with no 
significant difference between treated patients and those receiving placebo. No significant 
changes in AL T levels within the dose groups and the placebo group between baseline and the 
end of treatment were observed. Three patients (9%) (one each in the 0.05, 0.1 and 0.5 mg 
group) experienced asymptomatic hepatitis flares 16 weeks (2 patients) and 24 weeks (I 
patient) after withdrawal of entecavir. 
In conclusion, in this 28-day study of entecavir a pronounced decrease of HBV DNA was 
observed and there were no significant side effects in entecavir patients in comparison with 
placebo-treated patients. 
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Introduction 
Although the introduction of an effective vaccine against hepatitis B has drastically reduced the 
incidence of new infections, more than three hundred million people are affected by chronic 
hepatitis B infection world-wide. The infection may eventually lead to a substantial percentage 
of deaths due to cirrhosis with complications of liver failure and hepatocellular carcinoma (I). 
Alpha interferon has been the only registered therapy during recent years but it is effective in 
only one third of patients (2), requires parenteral administration and causes many side-effects 
especially in case of cirrhosis (3). Lamivudine, a cytosine nucleoside analogue, is an orally 
administered antiviral agent with few side-effects. It has recently been registered for the 
treatment of chronic hepatitis B infection (4-6). However, the development of mutations with 
decreased sensitivity of the virus for lamivudine (7-9), and the rebound of viral replication after 
withdrawal of the drug (10, 11) leave room for further improvement of nucleoside analogue 
therapy. The increase in viral replication after withdrawal of the drug is based on residual 
cccDNA inside the nucleus of the hepatocyte which is not affected by larnivudine (12, 13). 
Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of 
the hepatitis B virus (14-16).ln HepG2.2.15 cell lines, this compound has proved to be 30 times 
more potent than larnivudine in suppressing viral replication with an ECso of 4 nM compared to 
116 nM for larnivudine ( 14 ). The in vitro therapeutic index (a marker indicating the range of 
doses which can be applied safely without causing toxicity) is 8000 (15). In addition, 
incorporation of entecavir into cellular polymerases appears to be very inefficient thus 
bypassing an important cause of in vivo toxicity of nucleoside analogues. In chronically infected 
woodchucks, up to 8 log10 reduction in viral DNA has been observed after a mean of 32 weeks 
of therapy. Ten woodchucks which were treated for at least 14 months were both negative for 
cccDNA and HBcAg in the liver biopsy (17, 18). Five animals that were kept on maintenance 
therapy for up to three years showed sustained drops in woodchuck hepatitis virus (WHY) DNA 
with no evidence of resistance. In addition, \VHV DNA remained undetectable for 21 months 
after withdrawal of the drug (19). This may indicate that entecavir is not only capable of 
interfering with viral replication, but that it also has a direct effect on cccDNA. In untreated 
historical controls, all chronically infected woodchucks die of hepatocellular carcinoma within 
four years. In contrast, entecavir reduces the incidence of liver cancer resulting in prolonged 
survival of the animals. 
To be able to explore the initial antiviral effect and safety of entecavir in chronic hepatitis B 
patients, a placebo-controlle~ dose-escalating study was performed. 
Patients and methods 
Study design 
We conducted a double blind, placebo-controlled dose-escalating study of four dosages of 
entecavir 0.05 mg, 0.1 mg, 0.5 mg and 1.0 mg once daily. If proved eligible during the two 
screening visits, patients were treated for 4 weeks and followed up for 24 weeks after 
discontinuation of the drug. Each cohort started when the evaluation of the previous cohort 
treated with a lower dosage had proved to be safe. In each cohort, patients were randomly 
assigned to a dose of entecavir or placebo (8:2). Blinded randomisation was performed using 
a predetermined schedule maintained by the sponsor; bottle assignments were communicated 
by phone to the individual investigator. HBV DNA was assessed at 2 screening visits, day 1 
(baseline), week I, 2, 3 and 4 during dosing and week 2 and 4 post-dosing. HBV serology 
was obtained during initial screening, day I, week 4 and final post-dosing visit. Safety 
analysis, based on laboratory results, clinical evaluation of adverse events and physical 
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examination, was assessed on a weekly basis during therapy and monthly during follow-up. 
The protocol was approved by the Medical Ethics Committee of each participating center. All 
patients had to give written informed consent. 
Selection of patients 
Eligible patients included men and woman older than 16 years. Chronic hepatitis B infection 
was documented by HBsAg positivity in the serum for over 24 weeks before start of therapy. 
Each individual had to have an HBV DNA >20MEq/ml by the bDNA assay on 2 
determinations at least two weeks apart. Patients had to have a compensated liver disease as 
documented by serum transaminase activity below 5 times the upper limit of normal (ULN), 
serum albumin >30 g/1, serum bilirubin < 51.3 ~moVl, a prothrombin time which was not 
elongated for more than 3 seconds and the absence of significant ascites, hepatic 
encephalopathy or variceal bleeding. Both HBeAg positive and HBeAg negative patients 
were eligible. Previous antiviral therapy, such as alpha interferon and other nucleoside 
analogues, was permitted but had to be withdrawn 6 months before start of therapy in this 
trial. Patients were excluded if they were co-infected with the hepatitis C virus, the hepatitis D 
virus or the Human Immunodeficiency Virus (HIV); had another concomitant liver disease; 
had any signs or a history of pancreatitis; had received immunosuppressive therapy within six 
months before start of therapy. Both male and female patients had to practice a reliable 
method of contraception. 
Assays 
HBsAg, antibodies to HBsAg, HBeAg, antibodies to HBeAg, anti-HCV, anti-HDV and anti-
HIV were analyzed by an enzyme immunoassay (Abbott Diagnostics,Abbott Chicago). If the 
anti-HIV assay proved to be positive, an HIV Western blot (Biorad, Hercules, CA) was 
performed for confirmation. HBV DNA was detected with the Chiron branched DNA signal 
amplification assay (bDNA, Chiron, Emeryville, CA;) lower limit of detection of 0.7x 106 
genome equivalents/ml (geq/ml). HBV DNA was assessed with a sensitive PCR assay (Roche 
Monitor, limit of detection 400 geq/ml; Roche, Indianapolis, IN) at baseline and on day 28. 
Statistics 
The primary endpoint of this study was the proportion of subjects who had either a :;:::z log10 
reduction from baseline in their day 28 bDNA assay or who achieved undetectable levels of 
HBV DNA by the bDNA assay and a ~ log10 reduction from baseline in their day 28 Roche 
HBV DNA PCR assay. The secondary efficacy summaries were the proportion undetectable 
by the bDNA assay, and the mean log10 reduction from baseline by the bDNA assay regarded 
as a continuous parameter at days 7, 14. 21,28 and post-dosing days 14 and 28. 
For comparison between entecavir and placebo for endpoints represented by binary variables 
used Fisher"s exact test. Comparisons ofHBV DNA mean reductions were based on t-tests. 
One subject receiving entecavir 0.1 mg had a large spontaneous reduction in HBV DNA 
levels between the screening and baseline visits and was excluded from all of the efficacy 
analyses. The placebo subjects from each cohort in the sequential designs were pooled for 
comparison with each entecavir dose group. For binary end points, subjects who discontinued 
before day 28 because of an adverse event were assigned the failure value. Estimates and 
comparisons of mean differences were based on all available measurements at each time 
point, with measurements made after a subject who prematurely discontinued dosing was 
excluded. 
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Results 
A total of forty-two patients were randomized into this study. Initially, the protocol was 
scheduled to include doses of 0.1 mg (cohort I), 0.5 mg (cohort 2), 1.0 mg (cohort 3) and 2.5 
mg (cohort 4) of entecavir. However, after virologic evaluation of the 0.1 mg and 0.5 mg 
dosages of entecavir, it was decided to amend the protocol to exclude the highest dose of 2.5 
mg and instead to include a lower dose of0.05 mg (cohort 5). Eight, 9, 9, and 8 patients were 
treated with 0.05 mg, 0.1 mg, 0.5 mg, 1.0 mg, respectively. The evaluation was completed 
with a placebo group of 8 patients in which all data of placebo treated patients per cohort were 
pooled. Baseline characteristics are shown in Table 1. All entecavir groups and the placebo 
group were comparable with regard to sex and age. Fifty-two percent of patients were of 
Asian origin (n=22). Approximately fifty percent of patients were treatment-naiVe at start of 
entecavir therapy. In the two lower dose entecavir groups, half of the patients were previously 
treated with Jamivudine. The majority of patients were HBeAg positive (n=38, 90%). The 
baseline level of HBV DNA was comparable in all cohorts. Mean ALT level was above the 
Upper Limit of Normal (ULN) in all dosage groups. 
Table I Baseline demographics/characteristics, virology and chemistry 
Entecavir Entecavir Entecavir Entecavir Placebo 
0.05 mg 0.1 mg 0.5 mg l.Omg 
n=8 n=9 n=9 n=8 n=8 
Sex (M:F) 6:2 (75%M) 8:1 (89%M) 7:2 (78%M) 8:0 (100%M) 7:1 (88%M) 
Age (Mean years) 33.8 45.1 35.2 41.1 42.1 
Race 
Asian 5 (63%) 6(67%) 3(33%) 2 (25%) 6 (75%) 
Caucasian 2 (25%) 3 (33%) 4 (44%) 3 (38%) 2 (25%) 
Black 0 0 I (II%) 0 0 
Hispanic/ 0 0 0 3 (38%) 0 
Latino 
Other I (13%) 0 l (II%) 0 0 
Prior HBV therapy 4 (50%) 5 (56%) 4 (44%) 3 (38%) 2 (25%) 
IFN only 0 l (II%) 4 (44%) I (13%) I (13%) 
Lamivudine only 0 I (I!%) 0 0 0 
Larnivudine+IFN 4 (50%) 2 (22%) 0 2 (25%) l (13%) 
Lamivudine+ 0 I (I!%) 0 0 0 
polyclonal 
antibodies 
HBeAg positivity 7 (88%) 8 (89%) 7 (78%) 8 (100%) 8 (100%) 
Mean (log10 HBV 2.7 3.0 3.2 3.! 3.0 
bDNA) 
ALT (lUll, standard 77 (52) 78 (54) 106 (74) !24 (79) 86 (65) 
deviation) 
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Virological response 
All entecavir-treated patients showed a pronounced decline of serum HBV DNA after 4 
weeks of therapy. Treatment with 0.05 mg. 0.1 mg, 0.5 mg and 1.0 mg of entecavir resulted in 
a 2.21, 2.29, 2.81 and 2.55 mean log10 decline respectively versus 0.012 log10 increase in the 
placebo group (Table 2, Figure 1). Reduction in HBV DNA was similar between pre-treated 
patients and treatment-naive patients. HBV DNA below the limit of quantification of the 
bDNA assay was observed in 25% of patients in the two lowest dosage groups (0.05 and 0.1 
mg). in 33% of the patients treated with 0.5 mg of entecavir and in 13% of patients treated 
with 1.0 mg of entecavir. HBV DNA levels in the first 4 weeks post-dosing remained 
significantly lower for the two higher dosages of entecavir (0.5 and 1.0 mg) than for the 0.05 
or 0.1 mg dosages (p=0.005). Tluee entecavir-treated patients had undetectable HBV DNA by 
the bDNA assay 6 months post-dosing (2 at 0.5 mg and 1 at OJ mg). Two patients. 1 treated 
with 0.1 mg and 1 with 0.5 mg, lost HBeAg transiently. In these patients HBeAg was 
undetectable at day 28 and 4 weeks post-dosing, but again detectable at 6 months post-dosing. 
A third subject in the 0.05 mg group had lost HBeAg at 6 months post-dosing. 
Table 2 Response during 1 month of entecavir 
Entecavir Entecavir Entecavir 0.5 Entecavir Placebo 
0.05 mg 0.1 mg rna e 1.0 mg 
n=8 n=8u N=9 n=8u n=8 
~eanlog1ochangein -2.21 -2.29 -2.81 (0.21) -2.55 (0.17) +0.01 
HBVDNA (0.1 0) (0.33) (0.13) 
Patients reaching the 7 (88%) 4 (50%) 
primary endpointb 
8 (89%) 6 (75%) 0 
p-value for comparison 0.0001 0.077 0.0004 0.007 
to placebo 
Percentage undetectable 2 (25%) 2 (25%) 3 (33%) 1 (13%) 0 
b the bDNA assa 
a subjects discontinuing dosing before week 4 are excluded from the mean log10 change and 
are assigned failure for the analysis of the primary endpoint. 
b ~log10 reduction in HBV DNA by bDNA or undetectable HBV DNA by bDNA and <:log10 
reduction by Roche PCR.Level of detection ofbDNA was 0.7x106 Eq/ml. 
Liver transaminase lev·els 
~ean transaminase levels were elevated in all dosage groups at start of therapy (Table 1). 
Both at baseline and at the end of therapy, no significant difference was observed between the 
four dosage groups and placebo group. ~oreover, no significant difference between baseline 
and end of therapy levels of ALT were observed within the treatment groups. 
In two patients both in the 0.1 mg group AL T levels rose during the dosing period. Both 
patients were clinically asymptomatic while bilirubin stayed normal. Patient 1 entered the 
study with AL T level of 73 lUll, at the end of the treatment period AL T was 165 lUll .Patient 
2 entered the study with AL T level of 173 lUll which increased to 452 lUll, entecavir was 
discontinued with a subsequent drop in ALT. Patient 1 had a 2.8log reduction in HBV-DNA 
and patient 2 had 3.3 log reduction in HBV-DNA at study drug discontinuation mandated by 
the protocol. 
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Elevation of serum transaminases during the post-treatment follow-up are presented in Table 
3. During follow-up, three patients experienced a hepatitis flare withAL T levels which were 
more than 2 times baseline and greater than 10 times the upper limit of normal (ULN). None 
of these were associated with increase in bilirubin. In two patients (one patient treated with 
0.05 mg entecavir and one patient treated with 0.1 mg) the flare was observed at 16 weeks 
post dosing. Serum ALT levels had declined to 5.7xULN and 2.2xULN respectively at the 
last follow-up visit (24 weeks post-dosing). In the third patient, who had been treated with 0.5 
mg of entecavir, the flare was observed at 24 weeks post-dosing. No further follow-up data on 
this patient are available. 
Table 3 Elevation of serum transaminases in the post-treatment period of the study 
Entecavir Entecavir Entecavir Entecavir Placebo 
0.05 mg 0.1 mg 0.5 mg 1.0 mg 
n~S n~9 N~9 n~s n~s 
ALT 
>2x baseline value 3 (38%) 0 3 (33%) 2 (25%) 1 (13%) 
> 3x baseline value 3 (38%) 1 (11%) 2 (22%) 1 (13%) 0 
>lOx ULN' 1 (13%) 1 (13%) 1 (13%) 0 0 
AST 
>2x baseline value 2 (25%) 1 (11%) 3 (33%) 1 (13%) 1 (13%) 
>3x baseline value 2 (25%) l (!! %) 2 (22%) 1 (13%) 0 
>lOx ULN' 1 (!3%) 0 0 0 0 
'Upper Limit of Normal 
Safety 
Overall, entecavir was well tolerated and no dose-related or dose-limiting toxicity occurred. 
The majority of patients reported adverse events which were of mild to moderate severity but 
not significantly different from placebo-treated patients. Fatigue and headache were reported 
most frequently (Table 4).0ne subject in the 0.5 mg entecavir group experienced 
asymptomatic grade 1 elevation of amylase and a grade 3 elevation of serum lipase on day 8 
of therapy. This patient was kno\iVtl to have had elevation of lipase in the past. The study drug 
was withdra\iVtl for several days during which time both enzymes returned to normal and 
study drug was reintroduced and completed without further problems. 
During the dosing and post-dosing period, a total of 5 serious adverse events were reported, 
most of which could be related to progression of liver disease or external interference. One 
occurred in the first cohort (0.1 mg).This patient was diagnosed with hepatocellular 
carcinoma and pulmonary fibrosis six months post-dosing. In the second cohort (0.5 mg), one 
patient was hospitalized for a cholecystectomy for biliary stones three months after 
withdrawal of therapy and another patient experienced septic shock after a heroin overdose 1 
month post-dosing. In the third cohort ( 1.0 mg), one patient was withdra\iVtl from therapy after 
6 days as specified in the protocol due to persistent headache lasting longer than 12 hours. 
Extensive neurologic evaluation did not show any abnormalities. The other patient was 
involved in a car accident which required short-term hospitalization 2 months after 
withdrawal of therapy. No adverse events have been reported in the fifth cohort, the lowest 
dose applied. 
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Table 4 Most common non-serious adverse events reported on stud/. 
Entecavir Entecavir Entecavir Entecavir Placebo 
0.05 mg 0.1 mg 0.5mg l.Omg 
n=8 n=9 n=9 n=8 n=8 
Fatigue 2 (25%) 4 (44%) 2 (22%) 4 (50%) 3 (38%) 
Headache 2 (25%) 3 (33%) 4 (44%) 3 (38%) 3 (38%) 
Infection 2 (25%) 0 I (II%) 3 (38%) 0 
Abdominal pain I (13%) 3 (33%) I (11 %) 3 (38%) 2 (25%) 
Flu syndrome I (13%) 0 2 (22%) 4 (50%) 3(38%) 
Pharyngitis I (13%) 3 (33%) !(II%) 0 2 (25%) 
Nausea 0 2 (22%) I (11%) 3 (38%) 0 
a Includes events reported during 4-week dosing period plus 24-week post-dosing follow-up. 
Fig I Mean HBV DNA during therapy and I month follow-up. 
The present study reports experience with the new nucleoside analogue, entecavir, in patients 
with chronic hepatitis B. All dosages of entecavir showed a pronounced decline ofHBV DNA 
of more than two log after 4 weeks. In some patients, HBV DNA declined below the limit of 
detection (0.7x!06 Eq!ml) of the bDNA assay. Both interferon and lamivudine pre-treated 
patients and treatment-naive patients responded well to therapy. A transient loss of HBeAg 
occurred in two patients. One month of treatment is limited and not capable of inducing a 
pronounced viral suppression coinciding with HBeAg seroconversion. After withdrawal of 
entecavir in the 0.5 and 1.0 mg dose groups. HBV DNA remained significantly below 
baseline levels for four weeks. These data are in agreement with results from in vitro studies 
of entecavir and data on inhibition of viral replication in woodchucks (I 6.17).Rebound of 
virus after withdrawal of lamivudine occurs quickly. Return of HBV DNA to baseline was 
observed within 1 month of cessation of lamivudine in a phase II 24-week dosing study for 
the treatment of chronic hepatitis B patients (5). A comparison of studies in which patients 
were treated with lamivudine for 3. 6 and 12 months (4-6) showed that 12 months of therapy 
resulted in a more gradual rebound of viral load after discontinuation of therapy. However, 
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the latter study did not report on the extent of decline of HBV DNA with more sensitive 
assays. A larger percentage of patients with undetectable HBV DNA by PCR, may cause a 
slower return to baseline. In our study of entecavir, most of the patients in all dosage groups 
still had detectable HBV DNA by the bDNA assay at the end of 4 weeks of therapy although 
the higher dosage groups showed a more gradual return to baseline in the post-dosing period. 
As has been observed after withdrawal of lamivudine therapy (20), withdrawal of entecavir 
with a subsequent return of viral replication may induce a flare of serum transaminases. 
Spontaneous hepatitis flares occur at an annual rate of 27% in HBeAg positive patients (21) 
and larger patient populations should be evaluated to explore the relationship between 
entecavir therapy and the occurrence of hepatitis flares. None of the patients in the placebo 
group in our study population experienced a flare of serum transaminases, whereas 9% of 
patients who were treated with entecavir experienced transient hepatitis flare 16-24 weeks 
after withdrawal of entecavir. More pronounced suppression of HBV DNA may lead to a 
delay in recurrence in viral replication as well as a delay of the hepatitis flare. 
Nucleoside analogues are capable of interfering with the replication of the HBV since they 
have the same characteristics as natural nucleosides. However, this may also lead to 
interference with cellular polymerases. As has been seen with some other nucleoside 
analogues, inhibition of cellular enzymes may cause significant clinical events and even 
deaths (22-25). Entecavir has proved to have very low affinity for cellular DNA. In particular, 
mitochondrial DNA does not use entecavir at all. In this human study, no major adverse 
events were detected that could have been related to this characteristic of nucleoside 
analogues, but long-tenn studies will be needed to clarify this further. 
In conclusion, entecavir can be given safely for a short period of tiine and causes pronounced 
reduction in HBV DNA levels with a slower rebound after stopping therapy than has been 
reported for lamivudine. Entecavir should be studied in longer-tenn dosing trials to be able to 
evaluate more definitively its effect on viral replication and cccDNA~ and ultimately cure of 
chronic hepatitis B infection. 
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Summary 
Introduction Nucleoside analogues inhibit hepatitis B virus (HBV) replication. Entecavir, a new 
guanine nucleoside, has also sho'Wll to reduce cccDNA to undetectable levels in woodchucks 
chronically infected with hepatitis virus. Mathematical description of changes in viral load 
during and after therapy may help to understand the several events that take place during 
nucleoside analogue treatment. 
Patients and meLhods Ten chronic hepatitis B patients were evaluated with a mathematical 
model during and after withdrawal of four doses of entecavir. Blood was dra'Wll for HBV DNA 
measurement at frequent intervals. Non-linear modeling was used to fit individual patient data. 
Results The median effectiveness in blocking viral production is 96% (n=lO, range 87%-98%). 
The median half-life of viral turn-over was 16 hours (range 12-29). The median half-life of 
infected hepatocytes was 257 hours (=10.7 days) (n=9, range 112-762). Rebound of viral 
replication also followed a bi-phasic return to baseline levels. 
Conclusion Decay and rebound of viral concentration during and after entecavir therapy 
respectively. showed a bi-phasic pattern. Both can be described with a mathematical model. 
Data on levels of cccDNA in the liver in these patients could be helpful in supporting the 
parameters as calculated with the model. 
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Introduction 
In patients with chronic hepatitis B infection, annual clearance of HBsAg and HBeAg is 
estimated at I% and 10% respectively. HBeAg clearance, which is immune mediated, is 
improved by alpha interferon therapy resulting in HBeAg seroconversion in 30-40% of patients 
(I -4). Especially those patients with an immune-tolerant status, a large part of which is 
originating from Asian countries, do not show a favourable response to alpha interferon therapy 
(5). Recently, lamivudine has been registered as a second option for the treatment of chronic 
hepatitis B patients. Whereas HBeAg seroconversion is a solid end-point for alpha interferon 
therapy, durability of HBeAg seroconversion after withdrawal of lamivudine therapy needs to 
be evaluated yet. Reports on this end-point are contradictory (6-8). Recurrence of viral activity 
is attributed to the remnant covalently closed circular DNA ( cccDNA) inside the nucleus of 
hepatocytes which is not affected by larnivudine (9-1 0). 
Entecavir, a new guanine nucleoside analogue which is currently under investigation in phase II 
studies, is believed to be capable to interfere with cccDNA (ll-13). This consideration is based 
on observations in woodchucks chronically infected with the woodchuck hepatitis B virus. 
Short-term entecavir therapy markedly reduces cccDNA levels in the liver of woodchucks (14) 
and rebound of virus after withdrawal of therapy in woodchucks (15). Moreover, maintenance 
therapy in woodchucks with once weekly dosing regimens, is able to reduce cccDNA in the 
liver to undetectable levels (I 6). 
Mathematical modeling can be used to evaluate the mechanism of action of entecavir on both 
viral decline during and the return of virus after withdrawal of therapy. In previous modeling 
studies on the effect of nucleoside analogues in a chronic hepatitis B infection, it has been 
shown that viral decline can be divided into two phases: a first phase of turnover of free virus 
and a second phase of death of infected hepatocytes (17,18). Return of virus after withdrawal of 
therapy has never been evaluated in detail yet, but may be helpful in clarifying the mechanisms 
that take place during viral replication. 
We therefore conducted a study to model viral decline during entecavir therapy and viral return 
after withdrawal of entecavir therapy. 
Patients and Methods 
Study design 
All patients who were treated in the Academic Hospital Rotterd~ the Netherlands, in a 
study on the safety and efficacy of entecavir, were recruited for a study on viral dynamics. 
Patients were treated in a one month, double-blind, placebo-controlled dose escalating study 
on the safety and efficacy of entecavir (0.05 mg, 0.1 mg, 0.5 mg, 1.0 mg) versus placebo with 
a follow-up of six months. 
During the first month of therapy, HBV DNA was measured at day I at t=O and 8 hours, at 
day 2 at t=24 and 32 hours and at day 3, 4, 7. 10, 14, 21 and 28. Follow-up after withdrawal 
of therapy was documented with HBV DNA measurements at day 29. 30, 31, 32. 35, 38, 42, 
49, 56 and month 3, 4, 5 and 6. 
Selection of patients 
Patients were screened for eligibility on two occasions which had to be at least two weeks 
apart. Eligible patients included men and woman older than 18 years with a chronic hepatitis 
B infection as documented by HBsAg positivity in the serum for over 24 weeks before start of 
therapy and HBV DNA> 20 Meq/ml measured with the Chiron hybridization bDNA assay. 
Patients had to have a compensated liver disease as documented by laboratory and clinical 
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evaluation. Both HBeAg positive and HBeAg negative patients could be included. Previous 
antiviral therapy with alpha interferon, other nucleoside analogues or immunosuppressive 
therapy was permitted but these drugs had to be withdrawn 6 months before start of therapy in 
this trial. Patients were excluded if they were co-infected with the hepatitis C virus, the 
hepatitis D virus or the Human Immunodeficiency Virus; had another concomitant liver 
disease; had a history of a pancreatitis; had a history of any form of chronic headaches. Both 
male and female patients had to practice a reliable method of contraception. 
Assays 
HBV DNA was quantified with a Digene Hybrid Capture tube liquid hybridisation assay 
(calibrated on the EUROHEP standard (19)). lfHBV DNA declined below 1.5x!06 geq/ml (the 
limit of detection of this liquid hybridisation assay) during therapy, it was reassessed with the 
quantitative PCR (Roche, Amplicor Diagnostics, Almere, The Netherlands calibrated on the 
EUROHEP standard: lower limit of detection of 1000 geq/ml). HBV polymerase mutant 
analysis was performed with the INNO-LiPA strip (lnnogenetics. Ghent_ Belgium) (20). 
Modeling of viral decline and rebound 
A hi-phasic model previously applied for viral decline in chronic hepatitis C patients during 
alpha interferon therapy, was used to describe viral decay, by means of viral dynamic 
parameters, during entecavir therapy (21 ). In short, viral decline in this model is described by 
the following equation: 
In V(t)=ln Yo+ In {Aexp[-A.,t]+(l-A)exp[-Aot]}. which equals 
V(t)= Vo{Aexp[-A.,t]+(l-A)exp[-Aot]} where 
A., =slope of the first phase ofviral decline 
/...z =slope of the second phase of viral decline 
A = (EC-Ao)/( A.,-A.,) 
A.12 = Yo{(c+o)±[(c-o)'+4(!-z)(l-TI)co]"} 
V0 =initial viral load 
t =time 
8 = death rate of productively infected cells 
c =clearance rate of the free virus 
£ =effectiveness of entecavir in blocking virion production from infected cells 
11 =effectiveness of entecavir in blocking de novo infection of susceptible cells 
The hi-phasic return of virus after withdrawal of therapy was described by adapting a similar 
hi-phasic model as an inverse image of the hi-phasic decline in viral load during antiviral 
therapy: 
In V(t)'= In V01'-In {A 'exp[ -A.,'1t11]+(! -A11)exp[ -A./t11]}, which equals 
V(t)"= Vo' I {A11exp[-A.1't']+(l-A11)exp[-A.,'t'']} where 
V0# =viral load at the moment of withdrawal of therapy 
t~~' =time after withdrawal of therapy 
A11 =multiplier 
11.111 =slope of the first phase of viral rebound 
').._,:/ =slope of the second phase of viral rebound 
Statistics 
Patients were fitted individually. Due to the small sample size, all patients on entecavir 
therapy were evaluated as one group. Non-linear modeling was used to fit both the hi-phasic 
model and the inverse bi-phasic model, executed in the PROCNLIN in SAS 6.12. 
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The Mann-\Vhitney test was used to compare the difference between dose groups in rebound 
of viral replication after withdrawal of entecavir. The Kruskal-Wallis test was applied to 
calculate the difference in dose of entecavir with regard to parameters of viral return. 
Significant difference was achieved ifp<0.05. 
Results 
Eleven patients participated in the study: three patients received 0.05 mg, two 0.1 mg, two 0.5 
mg, three 1.0 mg and one placebo. Ten patients on entecavir therapy were evaluated for viral 
dynamic parameters of viral decay. Nine patients were evaluated for re-appearance of viral 
replication after withdrawal from therapy; one patient was withdrawn from therapy after I 
week because of a serious adverse event and not included in the analysis for return of viral 
replication. 
Table 1 Baseline characteristics 
Entecavir Entecavir Entecavir Entecavir 
0.05 mg 0.1 mg 0.5 mg l.Omg 
n=3 n=3 n=2 n=2 
Sex (M:F) 1:2 2:1 1:1 2:0 
Age (Years~ range) 23 (20-63) 39 (29-51) 38 (18-58) 27 (19-35) 
Race 
Asian 0 2 0 1 
Caucasian 1 1 
Other 2 0 1 0 
Previous lamivudine therapy 3 3 0 
HBeAg positivity 3 3 2 2 
HBV DNA (geq/ml) 4.15x109 6.24x108 8.34x109 1.70x109 
(median, range) 
ALTxULN 1 (1-1.5) 1.2 (1-3.4) 1.6 ( 1-2.2) 1.3 ( 1-1.5) 
median, range) 
Baseline characteristics are shown in table I. Six patients were male and 4 were female. The 
median age of the entecavir treated population was 35 years (range 18-63). Three patients 
were Asian and 4 patients Caucasian. The majority of patients (70%) were treated with 
lamivudine previously. Patient 4 and patient 10 had detectable mutant virus against 
lamivudine at start of entecavir therapy (YIDD and YVDD respectively). All patients were 
positive for HBeAg at start of therapy. Median baseline HBV DNA was 1.68x109 geq/ml 
(range 5.52xl07-1.50xl0 10), median elevation of ALT at baseline was 1.1 x the Upper Limit 
ofNormal (ULN) (range 1-3.5). 
Viral decay was determined during 28 days of entecavir therapy (Figure 1 ). The median 
effectiveness of blocking viral replication in all ten patients on entecavir therapy was 96% 
(range 87-98%). Tum-over of free virus was 16 hours (median~ range 12-29 hours, n=IO), 
turn-over of infected hepatocytes was estimated to be 10.7 days (range 5.2-31.8 days, n=9). 
For calculation of the viral decline during the second phase, patient 10 was excluded. This 
patient discontinued medication after 1 week due to a serious adverse event (Table 2). 
Entecavir was still capable of blocking viral replication in both patients with detectable 
lamivudine induced mutant virus (effectiveness in blocking viral production of 87% and 98% 
respectively). 
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Table 2 Dynamic parameters during and after one month ofentecavir therapy. 
Durin entecavir thera ' After withdrawal of entecavir thera 
Patient Effectiveness in Half-life first Half-life second Initial viral load Doubling time Duration of fast Viral load at the 
blocking viral phase phase (geq/ml) ofvims increase of viral end of follow-up 
production concentration 
(first phase of 
viral return) 
I; 0.05 mg 96% 24 hours 18.6 days 3.40xl08 95 hours 23 days 2.58xl09 
2; 0.05 mg 97% 18 hours 10.7 days 2.25x 109 129 hours 40 days 1.83x109 
3; 0.05 mg 96% 22 hours 15.2 days 6.63xl09 120 hours 30 days 4.21xl09 
4; 0.1 mg 87% 16 hours 31.8 days 1.92xl09 140 hours 16 days 1.05x109 
5; 0.1 mg 96% 13 hours 5.2 days 5.18x108 62 hours 14 days 2.32xl07 
6; 0.1 mg 89% 29 hours 25.0 days 7.03x108 102 hours 12 days 3.06x108 
7; 0.5 mg 97% 12 hours 4.7 days 1.44xl09 247 hours 101 days 2.24x109 
8; 0.5 mg 95% 13 hours 5.6 days 8.16xl09 244 hours 89 days 5.35x109 
9; 1.0 mg 92% 16 hours 10.7 days 3.61x107 230 hours 109 days 8.33x I 08 
1 0; 1.0 Ill 98% 17 hours N.A.* 3.04x109 N.A.* N.A.* N.A.* 
Median 96% 16 hours 10.7days 1.92x109 129 hours (~5 30 days 1.05x109 
da s 
*Not applicable; this patient was withdrawn from therapy after I 'veek. 
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Rebound of viral replication was followed until 6 months after withdrawal of therapy (n~9, 
excluding patient 10) (Table 2) (Figure 1). For mathematical description of return of viral 
concentration, the inverse of the hi-phasic model for viral decay describes the observed 
patient data accurately. The doubling time was 129 hours (median, range 62-247 hours) and 
the slope of the second phase of the rebound in viral concentration approaches zero in all 
patients (median 0.0304,range -D.OOO 166 -D.OO 158). The change from the first to the second 
phase of viral return was calculated to be at a median of30 days (range 12-109). No relation 
between viral load at the moment of withdrawal of entecavir, first and second phase of viral 
rebound with the dose of entecavir could be found. However, the 3 patients in the higher dose 
groups, showed a more gradual return of viral replication to baseline levels, than did the 6 
patients in the lower dose groups (p~0.024). 
Fig 1 Panel A: Viral decline during one month of entecavir therapy in 10 patients. 
X-axis: 0-30 days Y -axis: level of HBV DNA on a log scale 
Straight grey line: observed HBV DNA data 
Black dotted line: fitted HBV DNA data 
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Fig 1 Panel B: Viral rebound in 9 patients during six months after withdrawal of entecavir 
X-axis: 0-200 days Y-axis: level ofHBV DNA on a log scale 
Straight grey line: observed HBV DNA data 
Black dotted line: fitted HBV DNA data 
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Discussion 
The main action of nucleoside analogues is inhibition of viral replication through termination 
of the proviral chain. Lamivudine, which has been evaluated most extensively, has not shown 
to have any effect on cccDNA in in vitro systems (9,10). As a result, lamivudine therapy 
should be continued for a long time in order to be able to eliminate the virus through cell 
division and death of infected cells. It has been calculated that therapy should be continued 
for many years to achieve complete eradication of the virus from the liver (22). Unfortunately, 
indefinite prolongation of nucleoside analogue therapy will not be the answer to complete 
eradication of the virus due to a cumulative incidence of viral resistance ( 40~60% after two to 
three years of!amivudine monotherapy) (23-25). 
As a result, one should aim for a compound which does exhibit two features: interference with 
viral replication as well as a reduction of infected hepatocytes. Entecavir has proved to cause 
minimal side-effects during short-term application (26) and in vitro data imply the possible 
effect on cccDNA (14). Therefore, therapy with this drug may reduce the amount of infected 
cells to a greater extent and in a shorter amount of time. 
Although the results of this study are based on a small number of patients, the antiviral 
activity during short-term therapy with entecavir seems somewhat greater than during 
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lamivudine therapy (27) and lower than during adefovir dipivoxil therapy (17), although it 
should be realized that this is a head-to-head comparison and randomized studies are needed 
to identifY the actual differences in parameters between these nucleoside analogues. Our 
analysis is based on four low doses of entecavir during the first study in chronic hepatitis B 
patients; some of these doses might have been insufficient for the optimal treatment ofHBV. 
Moreover, the majority of our patients had previously failed lamivudine therapy which could 
also result in a less favorable response to re-introduction of another antiviral agent. Entecavir 
did show continuing activity in patients with detectable lamivudine-induced mutant virus. 
Theoretically, the second phase of more gradual decline in viral concentration may be 
influenced by death of infected hepatocytes and turn-over of cccDNA harboring cells. After 
the first 28 days of therapy, decline of viral concentration can be either slower than, equal to, 
or faster than observed during the second phase. We do not observe a difference in the slope 
of the second phase between lamivudine- and entecavir-treated patients in a head-to-head 
comparison. We could therefore speculate that in both lamivudine and entecavir treated 
patients, this second phase is primarily influenced by death of infected hepatocytes. If 
entecavir exhibits a direct effect on cccDNA, this effect may surface only during a longer 
treatment period. 
All 9 patients who were evaluated after withdrawal of therapy showed a bi-phasic pattern with 
an initial fast increase of viral replication followed by a more gradual increase (subject 4,5 
and 6) or a more or less steady state. This initial fast return of viral replication, which was 
calculated to last 30 days, could reflect the production capacity of the reservoir ofhepatocytes 
that is still infected with HBV followed by the infection of non-infected hepatocytes leading 
to a larger productivity. This second episode is more pronounced in some patients than in 
others. The part of the cccDNA pool which was not affected by entecavir can be used as a 
template from which the virus can re-iniriate replication once the inhibitor has been removed. 
This implies that a larger pool of still infected hepatocytes could result in a faster return of 
viral replication to baseline level. The second phase of this model represents a more or less 
steady state of viral production, counteracted by tum-over of free virus and infected 
hepatocytes. 
Patients who were treated with the two higher doses of entecavir (0.5 and 1.0 mg) showed a 
more gradual increase in HBV DNA to baseline levels than those patients who were treated 
with lower doses, even though viral load was suppressed to the same extent in all dose groups. 
Slower return of viral replication in the high dosed groups may therefore be due to a smaller 
remnant pool of infected hepatocytes and not to the extent of viral suppression in serum. The 
latter explanation has previously been used as an explanation for the slower return of viral 
replication after withdrawal of lamivudine therapy (28). 
In conclusion, these data show that both decay of viral concentration as well as rebound of 
hepatitis B viral concentration can be fitted with a mathematical model. Entecavir is effective 
in both patients infected with wildtype and variant hepatitis B virus. In the future, data on the 
actual amount of cccDNA in the liver of these entecavir treated patients could be helpful in 
supporting the outcome of the parameter estimates. 
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A minority of chronic hepatitis B patients benefit from a four month course of alpha 
interferon (IFN-a) through induction of HBeAg seroconversion (1-3). Moreover, IFN-o: 
therapy is also hampered by side-effects which require dose reduction in up to 20% of 
patients ( 4,5). Lamivudine, a recently registered, orally administered drug, shows a strong 
antiviral effect. Suppression of viral replication is pronounced in the majority of patients, 
resulting in normalization of serum transaminases and improvement of the histology activity 
index (HAl) on the Iiverbiopsy ( 6-8). However. monotherapy does have some definite 
disadvantages. 
In this thesis we tried to identify and describe the drawbacks of lamivudine monotherapy and 
to explore the first steps of new treatment strategies able to overcome these disadvantages. 
Modeling of.,: ira/ dynamics 
Comparison bet\Veen individual patient data in response to antiviral therapy is most often 
based on the absolute decline in viral load (9) or the percentage of HBeAg seroconversion 
during a predetermined period of observation. ( 6). This type of evaluation, however, does not 
take into account the dynamic process that occurs during antiviral therapy. Multiple studies in 
hepatitis C virus (HCV) infected patients, based on mathematical modeling, have shown to be 
predictive of both viral clearance and the likelihood of sustained response (10,11). We, and 
others ((chapter 2,3.4,6 and 8 of this thesis), 12,13) have applied these pre-existing models to 
evaluate data in hepatitis B virus (HBV) infected patients during antiviral therapy. 
Surprisingly, the bi-phasic model which is based on data in HCV patients during IFN-<X 
therapy (14) also describes the HBV data very well. Thus. the rough frame work of this 
model, which describes viral decline during a particular antiviral therapy is largely identical in 
both HBV and HCV infection. The hepatitis C virus, however, is a RNA-virus with a different 
replication cycle compared to HBV. Moreover, IFN-o: inhibits viral replication and induces 
hepatotoxicity as well, unlike most nucleoside analogues evaluated in this thesis. Their 
primary function is inhibition of viral replication. This stresses the fact that the mathematical 
model describes viral decline accurately. regardless of type of infection or therapy used. It 
should therefore be emphasized that we can obtain parameters from the model which we can 
fit into the biological processes, but we should not try to fit the biological process into the 
model. It is necessary to keep on expanding the model with additional parameters when new 
data, based on basic biological research, become available. A recent study does indeed 
include non-cytolitic loss ofhepatocytes (loss of cccDNA) into the model (15), but the value 
of this extra parameter cannot be calculated due to limitations in the technical options of the 
computerized models. Future molecular biologic studies could lead to even further expansion 
of the models. However, it is questionable whether this will provide us with a better 
understanding of the viral dynamic processes. We are both limited with regard to the technical 
applicability of the model and these extra parameters may not even change the values of the 
parameters which we can calculate at present (e.g. effectiveness in blocking viral production, 
tum-over of free virus and death rate of infected hepatocytes). So. at present the discussion 
focuses on leaving the model as it is, with all the limitations of this mathematical approach, or 
expanding the model making it more complex and more difficult to work with. Long-term 
follow-up data are needed, as in HCV modeling, to be able to relate initial response to therapy 
in the present model to long-term response in individual patients. 
Patient monitoring 
Some of the prerequisites for optimal modeling, in which we are different from the studies 
presented previously, should also be mentioned here. At first frequent well standardized 
quantitative HBV DNA determinations, are important for accurate modeling and should 
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become standard in all dynamic studies presented from this day onward; provided that this 
frequent sampling is achievable in clinical patient management. This will be the only way to 
be able to compare different studies with regard to the outcome of parameters. We would 
recommend minimal blood withdrawal at day 0, day 2, day 4 and day 7. In addition, all data in 
all patients should be analyzed simultaneously as the best statistical approach for comparison 
of groups of patients. All data presented so far (12,13,15), apply individual patient data from 
which mean group parameters are calculated. Since the outcome of both the group-wise 
analysis and the calculated mean of individual patients is similar (chapter 2). we suggest to 
use the approach of group-wise fitting in future studies. 
As has been observed in previous lamivudine studies ( 16). baseline ALT has proven to be an 
important determinant of HBeAg seroconversion. We were the first to describe a relation 
between baseline ALT and death of infected hepatocytes by including this baseline parameter 
into the model. When these different approaches regarding response to antiviral therapy are 
combined. death of infected hepatocytes appears to be an important determinant of viral 
eradication. From these data, the primary goal of lamivudine seems to be to suppress the viral 
load adequately enough for this event to take place. Two studies in chronic hepatitis B 
patients however (17-18), state that pre-treatment ALT levels are inversely correlated to the 
emergence of drug resistant mutants. These conflicting data stress the importance of 
evaluation of larger groups of patients with regard to viral dynamic parameters. It also 
indicates the need for evaluation of similarities between viral dynamic studies and studies in 
which response to therapy is based on. for example, decline in HBV DNA and HBeAg 
seroconversion. These latter studies describe the relation between a baseline factor and an 
event that occurs during long-term therapy only. In analogy to studies in HCV infections. pre-
therapy patient- and virus-characteristics become increasingly important. Recently. several 
studies on lamivudine therapy focussed on the response to lamivudine therapy and the 
emergence of mutations and their relation with viral subtypes or pre-existence of variant virus 
before start of therapy (19-21). Eventually this may lead to a tailor-made therapy approach in 
individual patients. 
HBV combination therapies 
Estimates of viral tum-over and the pre-treatment existence of variant virus in Human 
Immunodeficiency Virus (HIV) patients have shown that at least three different nucleoside 
analogues should be applied in order to be able to prevent the emergence of drug resistant 
mutants during antiviral therapy (22). In this thesis, we combined lamivudine with either 
famciclovir or ganciclovir in a small number of patients. These combinations, however, did 
not result in a more pronounced decline in viral replication than lamivudine alone. In vitro 
and in vivo studies on the combination of lamivudine and famciclovir (23-25) did show the 
superiority of lamivudine-famciclovir combination therapy over lamivudine monotherapy. 
This in vivo observed difference in response should however be interpreted with caution as 
the group of patients studied was small. Moreover. the majority of patients in our study had 
been pre-treated with lamivudine which may have caused a less favorable response to the 
addition of famciclovir because similar mutations in the polymerase of the HBV for 
lamivudine and famciclovir have been described (26). Therefore. it is of importance to 
combine nucleoside analogues of distinctive origin (cytosine, thymidine, guanine, adenine) in 
order to prevent competitive inhibition of the polymerase. In addition, analogues that are 
combined should not be capable of inducing the same mutations in the polymerase of the 
HBV. At this moment. this profile is met by entecavir and adefovir dipivoxil, which are both 
evaluated in clinical studies. Combinations of lamivudine and adefovir dipivoxil have been 
tested in in vitro systems and have proved to be synergistic (23). Adefovir dipivoxil expresses 
continuing activity against HBV variants induced by lamivudine (27-28). A first in vivo study 
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has also shown continuing effect of adefovir dipivoxil on lamivudine resistant HBV in liver 
transplant patients (29). However, present study designs aim at rescue therapy in patients who 
have already developed a lamivudine induced HBV variant. These patients will still be treated 
with one optimally active antiviral compound only. Therefore, future therapies should start 
with combinations of nucleoside analogues simultaneously and not in an overlapping ''add-
on'' strategy. Combinations of lamivudine and equally or stronger virus suppressive agents 
like entecavir and adefovir dipivoxil are better options than famciclovir or ganciclovir, since 
the latter have only proved to be moderate suppressors of HBV replication if applied as 
monotherapy (30,31 ). The best option in the near future is either a combination of lamivudine 
and adefovir dipivoxil or adefovir dipivoxil monotherapy. Monotherapy with the latter 
nucleoside analogue may be an option since a recent study showed that after 1 year of 
therapy, the incidence of clinical relevant mutations is very low (32). 
New nucleoside analogues that are under pre-clinical evaluation (L-FMAU) (33,34) or have 
just recently been applied in clinical trials ( emtricitabine, FTC) could also be a candidate for 
combination therapy. L-FMAU is an uracil nucleoside analogue which was investigated for 
its effect on cccDNA in chronically infected woodchucks. Its EC50 proves to be a little less 
than lamivudine, but 10 times better than famciclovir. No effect on cccDNA other than the 
division and loss of infected hepatocytes during antiviral inhibition can be observed. FTC, a 
cytosine nucleoside analogue similar to lamivudine is also a strong virus suppressive agent 
(35,36). During 24 weeks of therapy, 25-100 mg of FTC induces 2.3-3.0 log reduction in viral 
replication with a favorable safety profile (37). 
Complete eradication of the hepatitis B virus in once chronically infected patients can most 
probably not be achieved. Several studies in liver-transplantation patients and in patients who 
have cleared the virus from serum, have shown the persistent presence of low levels of HBV 
in the liver.(38-42). Induction of immunotolerance should therefore be the major goal of 
antiviral therapy in chronic hepatitis B patients. If this can be achieved, progression of the 
liverdisease will be prevented. Suppression of the virus to a large extend and for a long time 
may be followed by the natural turnover of infected hepatocytes which may eventually 
establish viral eradication. On the other hand, a suppressor of viral replication combined with 
an agent that has immunological capacity, could speed up the process of viral eradication. 
Previous studies on lamivudine combined with alpha interferon in selected patients suggest 
the superiority of the combination therapy over either monotherapy alone (43,44). Present 
studies focus on the effect of the combination of lamivudine and PEG-interferon. PEG-
interferon has the advantages of less frequent administration and supposedly fewer side-
effect. This long-term combination therapy may enhance the HBeAg seroconversion ratio. 
Entecavir, which is, like lamivudine, an inhibitor of viral replication, may have some direct 
effect on cccDNA as well (45,46). If this assumption can be proved during in vivo application, 
entecavir could directly eradicate the most stable form of the virus from the liver. Adefovir 
dipivoxil is known to induce stimulation of NK-cells which in tum could also result in a 
higher turnover of infected hepatocytes (47). 
HIV-HBV co-infection 
In this thesis, we describe a specific group of HIV -HBV co-infected patients, in which the 
emergence of mutations becomes increasingly important. A considerable percentage of 
immunocompetent patients develops a flare of serum transaminases ( 48). Although only one 
patient in our cohort experienced a hepatic flare without liver decompensation, recent reports 
(49,50) emphasize the fact that these flares may have serious consequences, even in this 
immunodeficient patient population. We determined a decrease in CD4-cells during HAART 
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as a factor correlated to the faster clinical detection of drug resistant mutants. A non-response 
to HAART should therefore be observed cautiously, and a switch to an alternative therapy 
(e.g. adefovir dipivoxil (51)) may be needed early during therapy. Whether one should start 
with lamivudine in this patient group, should probably be based on the same considerations as 
in immunocompetent patient. We observed more or less equal percentages of mutations in our 
patient group and HBV mono-infected patients. Therefore, the fear of occurrence of mutations 
should not primarily lead the decision whether to start with lamivudine or not. Lamivudine 
should be introduced in patients with active liver disease, in which the progression to cirrhosis 
could be prevented. On the other hand, one should probably not initiate lamivudine-therapy in 
co-infected patients with active liver disease in whom therapy for the HIV infection is not yet 
needed. Lamivudine monotherapy results in resistance of the HIV for lamivudine after a few 
weeks of therapy (52). This could hamper future HIV treatment strategies in these patients 
and this situation should, if possible. be avoided. 
Finally 
In conclusion, future treatment strategies in chronic HBV patients could include combination 
therapies with several nucleoside analogues. monotherapy with nucleoside analogues which 
have a direct effect on cccDNA in vivo or nucleoside analogue(s) in combination with an 
immunomodulating agent. 
Frequent patient monitoring during the initial days of therapy is essential to arrive at a tailor-
made therapy approach. Mathematical modeling, as described in this thesis, taking into 
account patient related factors like AL T and BMI can be used to select dosages of individual 
drugs, and to compare several combination therapies. 
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Summary 
Lamivudine, a suppressor of hepatitis B viral replication, has been studied intensively in 
several large studies. Recently, it has been licensed for its antiviral effect in patients with 
chronic hepatitis B infection. This antiviral effect may cause reduction of liver inflammation 
and result in an arrest of liver disease progression or even improvement of liver inflammation 
and fibrosis. In this thesis, we focussed on the possible causes of diminished response to 
lamivudine, on methods to evaluate the difference in response to nucleoside analogue therapy 
and we explored a number of ways to improve existing antiviral therapies. 
Following the concept of oral applicable antiviral therapy, the search for new nucleoside 
analogues has been intensified and has resulted in many strong antiviral compounds. In the 
first chapter we describe the similarities and differences between five nucleoside analogues 
which are applied in clinical studies. These nucleoside analogues are capable of interfering 
with the replication of the hepatitis B virus because of their resemblance to natural 
nucleosides. However, this quality also enables them to induce serious adverse events. 
Therefore, it is important to focus on new antiviral compounds which exhibit a positive 
balance between effectiveness and safety. 
A mathematical model has been applied to describe hepatitis C viral decline during interferon 
therapy. In chapter 2 we use this same bi-phasic model to describe hepatitis B viral decline 
during lamivudine therapy and compare this model with an exponential model and a bi-phasic 
model with a flat second phase. The latter two models proved to be less accurate. For 
evaluation, a group-wise analysis is the best statistical approach due to population 
interactions. Differences in results between individual fitting and group-wise fitting were 
minimal. In chapter 3, high and low dose of lamivudine were compared with the bi-phasic 
model. The baseline factors ALT and previous lamivudine therapy were significantly related 
to viral decline during the second phase and viral decline during the first phase respectively. 
Since the reasons behind a suboptimal response to lamivudine are not clear, we studied the 
first step in the phannacokinetic process oflamivudine therapy. Lamivudine levels in blood of 
patients who participated in a previous study on the efficacy of lamivudine. were compared 
with a reference curve. Concentrations of lamivudine 6 hours after intake in the study group 
were within the range of the reference curve. Further research into the concentrations of active 
lamivudine-triphosphate inside the hepatocyte is needed to elucidate the causes of differences 
of viral decline between patients (chapter 4). 
In chapter five we describe the emergence of mutations which is one of the known causes of a 
diminished response to lamivudine. Since the Human Immunodeficiency Virus (HIV) 
infected population shows a prolonged survival after the introduction of Highly Active 
AntiRetroviral Therapy (HAART). more focus should be placed on the Hepatitis B Virus 
(HBV) as an important factor of co-morbidity. We report on two HIV-HBV co-infected 
patients; one patient developed a mutation to lamivudine during prolonged lamivudine 
therapy and the other a hepatitis flare after the withdrawal of lamivudine. These cases show 
the importance of monitoring both HBV and HIV infection carefully (chapter 5A). In a multi-
center study, a cohort ofHIV-HBV co-infected patients on long-term lamivudine therapy was 
evaluated for the emergence of mutations. The calculated incidence of 25% at one year and 
52% at two years is roughly similar to the immunocompetent patient population. Baseline 
Body Mass Index and decline of CD4 cells during therapy were significantly related to the 
emergence of mutations (chapter 5B). In the last part of this chapter we describe the virus 
suppressive potential of famciclovir in one patient who had developed a YIDD mutation 
during long-term lamivudine therapy (chapter 5C). 
Because of the emergence of mutations during long-term lamivudine therapy and the probable 
failure of lamivudine to eradicate the HBV from the liver, there is a need to explore new 
134 
Summary 
treatment strategies. First of all, we applied combinations of nucleoside analogues to aim at 
more pronounced virus suppression or to prevent the emergence of mutations. We evaluated 
the response to lamivudine monotherapy, lamivudine-ganciclovir and lamivudine-famciclovir 
combination therapy by means of the bi-phasic model. No significant difference between the 
three groups was observed. This may be explained by the sample size or the duration of 
therapy but our impression is that these combinations are not of major importance compared 
to lamivudine monotherapy (chapter 6). 
Thereafter, we studied a new nucleoside analogue, entecavir, with potential effect on 
covalently closed circular DNA (cccDNA), the most resistant form of the HBV inside the 
liver. We evaluated entecavir in a one month, placebo-controlled, dose-escalating study on the 
safety and efficacy offour doses of entecavir. All doses (0.05 mg, 0.1 mg, 0.5 mg and 1.0 mg) 
resulted in a pronounced decline of HBV DNA (2.21, 2.25, 2.81 and 2.42 log respectively) 
(chapter 7). 
Patients in the previous study who were treated in our hospital also participated in an ancillary 
study on viral dynamics. We evaluated the dynamics of viral decay of the HBV during 28 
days of entecavir and the return of viral replication until 6 months after withdrawal of 
entecavir therapy. Both viral decay and viral rebound are hi-phasic; calculation of dynamic 
parameters could support the biological phenomena that occur during and after withdrawal of 
antiviral therapy (chapter 8). 
At the moment, combinations of antiviral drugs are being evaluated for the treatment of 
chronic HBV infections, similar to the development of combination therapies for the HIV 
infection a few years ago. Mathematical modeling taking into account differences in baseline 
parameters like ALT and previous treatment is capable of describing the difference between 
treatment strategies, as well as clarifying the mechanisms which are responsible for the 
reaction to the different antiviral drugs. Modeling could be a useful tool to eventually 
discover the most appropriate therapy for chronic hepatitis B patients. 
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Samenvatting 
Lamivudine is een geneesmiddel dat de vermenigvuldiging van bet hepatitis B virus (HBV) 
remt. Het middel is uitgebreid onderzocht in verscheidene grote studies. In 2000 is bet 
geregistreerd als behandeling van chronische hepatitis B patienten. Door de 
virusonderdrukkende werking kan de leverontsteking verbeteren, de progressie van de 
leverzieh..'te worden voorkomen of zelfs de mate van fibrose afuemen. In dit proefschrift 
hebben wij ons gericht op de mogelijke oorzaken van een verminderde respons op 
lamivudine, op methodes om het verschil in respons op therapie met nucleoside analoga te 
evalueren en op bet verder verbeteren van de reactie op bestaande en nieuwe antivirale 
therapie. 
Oraal toe te dienen medicatie heeft voordelen boven parenterale toediening en in dit Iicht is er 
intensief gezocht naar therapie in tabletvorm, wat heeft geresulteerd in een groot aantal 
krachtige antivirale middelen. In het eerste hoofdstuk bescbrijven we de overeenkomsten en 
verschillen tussen de vijf belangrijkste orale nucleoside analoga die worden gebruik.'t in 
klinische studies. Deze nucleoside analoga zijn in staat om de vennenigvuldiging van het 
HBV te remmen omdat ze grote gelijkenis vertonen met natuurlijke nucleosiden. Deze 
eigenschap zorgt ecbter ook voor emstige bijwerkingen. Daarom is het belangrijk om uit te 
kijken naar nieuwe antivirale middelen met een positieve balans tussen effectiviteit en 
veiligheid. 
Een wiskundig model is gebruik.'t om virus-afname tijdens interferon-behandeling voor 
hepatitis C patienten te bescbrijven. In hoofdstuk 2 maken we gebruik van dit twee-fase 
model om de a:fname van het hepatitis B virus tijdens lamivudine-bebandeling te bescbrijven 
en om het model te vergelijken met een exponentieel model en een twee-fase model met een 
horizontale tweede fase. De laatste twee modellen leverden de minst precieze bescbrijving op. 
Om virusafname van groepen patienten te bescbrijven, is groepsgewijze analyse de beste 
statistiscbe methode voor evaluatie van patientenpopulaties in verband met populatie-
interacties. Het verschil tussen individuele nfits" en groepsgewijze "fits" blijken minimaal. In 
hoofdstuk 3 zijn een hoge en een lage dosis lamivudine vergeleken met behulp van bet twee-
fase model. De uitgangswaarden ALT en eerdere lamivudine-behandeling waren significant 
gerelateerd aan virusafname tijdens respectievelijk de tweede en eerste fase. 
Omdat de oorzaken van sub-optimale respons op lamivudine behandeling niet geheel 
duidelijk zijn, bebben we de eerste stap in het phannacokinetische proces van lamivudine 
bestudeerd. Lamivudine spiegels in bloed van patienten die eerder deelnamen aan een studie 
over de effectiviteit van lamivudine, werden vergeleken met een referentiecurve. 
Concentraties van lamivudine zes uur na inname in de studiegroep en de referentiegroep lagen 
binnen dezelfde grenzen. Verder onderzoek naar concentraties van de actieve metaboliet 
lamivudine-trifosfaat, is nodig om de oorzaken van sub-optimale respons op lamivudine 
behandeling in bepaalde patii!nten op te helderen (hoofdstuk 4). 
In hoofdstuk vijf beschrijven we bet optreden van mutaties, een van de bekende redenen van 
een verminderde respons op lamivudine. Omdat de overleving van de Human 
Immunodeficiency Virus (HIV) geinfecteerde populatie na de introductie van Highly Active 
AntiRetroviral Therapy (HAART) Ianger is geworden, dient meer aandacht te worden besteed 
aan een hepatitis B infectie als een belangrijke factor van co-morbiditeit. We beschrijven twee 
HIV-HBV gecoinfecteerde patienten: een patient ontwikkelde een HBV-mutatie tegen 
lamivudine na langdurige lamivudine-behandeling en de ander een hepatitis flare na staken 
van lamivudine behandeling. Deze casus benadrukken bet belang van goede controle van 
zowel de HIV als de HBV infeetie (hoofdstuk SA). In een multi-center cohort studie hebben 
we een cohort van HIV -HBV gecoinfecteerde patienten die gedurende langere tijd met 
lamivudine werden behandeld, geevalueerd voor het optreden van mutaties. De berekende 
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incidentie van 25% na 1 jaar en 52% na twee jaar zijn grof\:veg hetzelfde als in de niet-
immuun gecompromitteerde patienten populatie. Baseline Body Mass Index en afuame van 
CD4 cellen tijdens behandeling waren beiden significant gerelateerd aan bet optreden van 
mutaties (hoofdstuk 5B). In bet laatste dee! van dit hoofdstuk beschrijven we de 
virusonderdrukkende potentie van famciclovir in een patient die een YIDD mutatie had 
ontwikkeld tijdens langdurige lamivudine behandeling (hoofdstuk 5C). 
Vanwege bet optreden van mutaties tijdens langdurige lamivudine-behandeling en bet 
mogelijke onvermogen van lamivudine om bet HBV ccc-DNA te venvijderen uit de lever, is 
bet noodzakelijk om nieuwe behandelingsstrategieen te ontwikk.elen. In eerste instantie 
bebben we combinaties van nucleoside analoga toegepast om een krachtiger onderdrukking 
van het virus te bewerkstelligen en het ontstaan van mutaties te voorkomen. We evalueerden 
de respons op lamivudine-monotherapie, lamivudine-ganciclovir- en lamivudine-famciclovir-
combinatie-therapie met bebulp van het twee-fase model. Er werd geen significant verschil 
tussen de verschillende groepen gevonden. Dit zou k.'Urlllen worden verklaard door de 
beperkte groepsgrootte of de korte duur van behandeling maar onze ind.ruk, gebaseerd op deze 
beperkte dataset, is dat deze combinaties niet van groot kliniscb belang zijn in vergelijking 
met lamivudine monotherapie (hoofdstuk 6). 
Daarna bestudeerden we een nieuw nucleoside analogon, entecavir, welke mogelijk effect 
heeft op de meest resistente vorm van bet HBV in de lever: bet covalently closed circular 
DNA (cccDNA). We onderzocbten entecavir in een 1 maand durende, placebo-
gecontroleerde, dosis-oplopende studie naar de effectiviteit en veiligheid van vier doseringen 
van entecavir. Aile doseringen (0.05 mg, 0.1 mg, 0.5 mg en 1.0 mg) resulteerden in een 
uitgesproken onderdrukking van het HBV DNA (2.21, 2.25, 2.81 en 2.42 log respectievelijk) 
(hoofdstuk 7). 
Patienten in de voorafgaande studie die in ons ziekenhuis werden bebandeld namen ook deel 
aan een studie over virale dynamiek. We evalueerden de virusafuame gedurende 28 dagen 
bebandeling met entecavir en de terugkeer van virusvermeerdering tot 6 maanden na staken 
van entecavir-bebandeling. Zowel virusafuame als terugkeer van virusvermeerdering vertonen 
elk een twee-fasen verloop. Berekening van dynamiscbe parameters zou de biologische 
verschijnselen die optreden tijdens en na bebandeling kunnen ondersteunen (boofdstuk 8). 
Conform de ontwikkeling van antivirale tberapie voor HIV infecties, worden op dit moment 
de eerste combinaties van virusonderdrukkende middelen voor HBV -infecties geevalueerd. 
Wiskundige modellering, rekening houdend met populatieverschillen in serum AL T en 
eerdere bebandeling objectiveert de verscbillen tussen de bebandelingen en verheldert 
mogelijk de biologiscbe mecbanismen die ten grondslag liggen aan de respons op de 
verschillende antivirale middelen. Op deze marrier gebruikt kan de modelmatige benadering 
een bruikbaar hulpmiddel zijn om uiteindelijk tot een optimale bebandelingsstrategie voor 
chronische hepatitis B patienten te komen. 
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Abbreviations 
3TC 
AIC 
AIDS 
ALT 
2'3. wdideoxy-thiacytidinc (lamivudinc) 
Akaikc's Information Criteria 
Acquired ImmunoDcficieny Syndrome 
alanine aminotransferase 
AST aspartate aminotransferase 
AUC arcaundcrthccurve 
AZT zidovudine 
bis-POM-PMEA bis(pivaloyloxymcthyl)-(9-(2-phosphonylmcthoxycthyl)adcninc) 
BMI body mass index 
CC50 50% cytotoxic concentration 
cccDNA covalently closed circular DNA 
CI confidence interval 
Ciso 
CMY 
ddC 
dGTP 
DR! 
DR2 
dTTP 
ECso 
geq 
'j(iT 
HAART 
HAY 
HBY 
HBeAg 
HBsAg 
HCY 
HOY 
HIY 
HPLC 
!U 
Ki 
Km 
Ki!Km 
MEq 
mRNA 
NNRTI 
od 
PBMC 
PCR 
PEU 
PT 
S.d. 
S.C. 
TY~ 
ULN 
UY 
WHY 
YIDD 
YMDD 
YVDD 
50% inhibitory concentration 
cytomegalovirus 
zalcitabinc 
dcoxyguaninc 5'-triphosphatc 
direct repeat region 1 
direct repeat region 2 
dcoxythymine 5'-triphosphate 
50% effective concentration 
genome equivalents 
gamma glutamyl transferase 
Highly Active AntiRctroviral Therapy 
hepatitis A virus 
hepatitis B virus 
hepatitis B envelop antigen 
hepatitis B surface antigen 
hepatitis C virus 
hepatitis D virus 
human immunodeficiency virus 
high pressure liquid chromatography 
international units 
inhibitory constant 
Michaelis constant 
ratio which expresses competitive inhibition of a nucleoside analogue and a natural nucleoside 
mega equivalents 
messenger ribonucleic acid 
NonwNuc\eoside Reverse Transcriptase Inhibitor 
once daily 
peripheral blood mononuclear cells 
Polymerase Chain Reaction 
Paul Ehrlich Institute Units 
prothrombin time 
standard deviation 
standard error 
halfwlife 
Upper Limit of Normal 
ultra violet 
woodchuck hepatitis virus 
thyrosine isoleucine aspartate aspartate 
thyrosine methionine aspartate aspartate 
thyrosine valine aspartate aspartate 
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